 
Principal Investigator: [CONTACT_70798], Grace, Hsiao-Wei                                                                                             A Pi[INVESTIGATOR_450777] 
 
[ADDRESS_574742] Protocol V5.0 6 May 2022  
      
[STUDY_ID_REMOVED] 
Protocol 
A Pi[INVESTIGATOR_450778] 5.0 
5/6/2022 
 
 
  
 
 
Grace H. Lo, MD MSc 
Baylor College of Medicine 
Michael E. DeBakey VA Medical Center 
Houston, TX 
    
 
Principal Investigator: [CONTACT_70798], Grace, Hsiao-Wei                                                                                             A Pi[INVESTIGATOR_450777] 
 
[ADDRESS_574743] Protocol V5.0 6 May 2022  
History of Protocol Versions: 
Version  Date Summary of Revisions Made Rationale 
V 1.0 10-30-18 N/A Original version created prior to 
receiving funding from NIAMS. 
V 2.[ADDRESS_574744] 
something to track and not and adverse event, this will improve the 
likelihood that our primary assessor 
can maintain blinding. 
V 4.0 7-8-20 Revisions to address the 
comments that arose from 
the KAI Introductory Site 
Visit. Updated after the KAI Introductory 
Site Visit Meeting. 
V 4.1 9-2-20 UADE defined. 
Revision made regarding 
how we will determine our n 
for the study. Revisions to address the requests 
made based on the large round of 
revisions based on the KAI 
Introductory site visit.  Issues raised included defining UADE – 
 
Principal Investigator: [CONTACT_70798], Grace, Hsiao-Wei                                                                                             A Pi[INVESTIGATOR_450777] 
 
[ADDRESS_574745] Protocol V5.0 6 May 2022 unanticipated device effects and 
revising our target recruitment 
numbers. 
V 5.0 5/6/2022 Reduction of target N. The 
addition of NYU as an 
additional clinical site. They 
will perform all the same 
clinical activities, but will not be performing any blood 
draws or imaging.   Changes made to address 
challenges in recruitment and a 
change in personnel.  
 
  
 
Principal Investigator: [CONTACT_70798], Grace, Hsiao-Wei                                                                                             A Pi[INVESTIGATOR_450777] 
 
[ADDRESS_574746] Protocol V5.0 6 May 2022  
Contents 
Abbreviation Glossary  .............................................................................................................................. .............................. 7 
STATEMENT OF COMPLIANCE  .............................................................................................................................. ................ 11 
DATA COLLECTION INFRASTRUCTURE / SIGNIFICANT STATEMENT OF ATTESTATION  ...................................................... 12 
1.0  Executive Summary  .............................................................................................................................. ......................... 12 
1.1 Schedule of Ac tivities (SoA) .............................................................................................. .......................................... 14 
2.0  Background and Significance  .............................................................................................................................. .......... 15 
3.0  Study Objectives  .............................................................................................................................. .............................. 19 
4.0  Study Design  .............................................................................................................................. .................................... 22 
4.1 Overview of th e Proposed Study. ........................................................................................... .................................... 22 
4.2 Investigators/Co-Investigato rs/Collaborators /Consultants .................................................................. ...................... [ADDRESS_574747] Particip ation Duration ............................................................................................ ........................................ 25 
5.0  Study Population  .............................................................................................................................. ............................. 26 
5.1 Recruitment of Participants. .............................................................................................. ......................................... 26 
5.2 End of Study Definition ................................................................................................... ............................................ 27 
5.3 Inclusion/Excl usion Crit eria. ............................................................................................. ........................................... 27 
5.4 Screening Failures. ....................................................................................................... ............................................... 28 
5.5 Retention/Adherence Strategies ............................................................................................ .................................... [ADDRESS_574748] of Care. ......................................................................................................... ............................................... 31 
6.5 Traction Therapy. ......................................................................................................... ............................................... 32 
6.6 Definition of Enroll ment Into the Study. .................................................................................. ................................... 34 
6.7 Opportunity for a Doctor’s Visit. ......................................................................................... ........................................ 34 
6.8 Feasibility of Implementing a Finger Tracti on Orth osis. ................................................................... .......................... 34 
6.9 Potential for Bi as. ....................................................................................................... ................................................. 34 
6.10. Assessment of Compliance ................................................................................................ ...................................... 35 
6.11 Training of Research Coordina tors and Occupati onal Therapi[INVESTIGATOR_11437]............................................................. ................ 35 
 
Principal Investigator: [CONTACT_70798], Grace, Hsiao-Wei                                                                                             A Pi[INVESTIGATOR_450777] 
 
[ADDRESS_574749] Protocol V5.0 6 May 2022 7.0 Study Intervention Discontinuation/ Participant Discontinuation / Withdrawal  ....................................................... [ADDRESS_574750]  include: .............................................................................. ................................... 40 
8.4. Structural Modifi cation Asse ssments ...................................................................................... .................................. 41 
8.5 Proof of Concep t. ......................................................................................................... ............................................... 42 
8.6 Monitoring Body Member ship and A ffiliation ................................................................................ ............................ 42 
8.7 Safety Reporting .......................................................................................................... ................................................ 42 
8.7.a Adverse Even t Definitions ............................................................................................... ..................................... 42 
8.7.b Adverse Ev ent Reporting ................................................................................................. .................................... 43 
8.7.c Severity Assessmen t of Adverse Event..................................................................................... ............................ 43 
8.7.d Relatedness Assessmen t of Adverse Event. ................................................................................ ......................... 43 
8.7.e Definition of Expected an d Unexpected Adverse Events. ................................................................... ................ 44 
8.7.f Determination of whether or no t an Adverse Even t is Serious. ............................................................ ............... 44 
8.7.g Time period and frequency fo r event assessment and follow up. ........................................................... ........... 44 
8.7.h Timing of reporting of AEs and SAEs to monitoring entities .............................................................. ................. 45 
8.8 Unanticipated Problem Reporting ............................................................................................... ............................... 46 
9.0 Statistical Considerations  .............................................................................................................................. ................. 49 
10.0 Supporting Documentation and Operational Considerations  .................................................................................... 50 
10.1 Protocol Deviatio ns ...................................................................................................... ............................................. 50 
10.2 Study Discontinua tion and Closure ........................................................................................ ................................... 50 
10.3 Data Archiving / Quality Control / Qualit y Assurance...................................................................... ......................... 51 
10.4 Publication and Da ta Shari ng Policy....................................................................................... ................................... 51 
10.5 Manual of Operations ..................................................................................................... .......................................... 52 
10.6 Study Timeline ........................................................................................................... ................................................ 52 
10.7 Participan t Safety ....................................................................................................... ............................................... 54 
10.7.a Risks to Hu man Subjects ................................................................................................ .................................... 54 
10.7.b Study Procedures, Materi als, and Pote ntial Ri sks ....................................................................... ...................... 55 
 
Principal Investigator: [CONTACT_70798], Grace, Hsiao-Wei                                                                                             A Pi[INVESTIGATOR_450777] 
 
[ADDRESS_574751] Risks .............................................................................................. ..................................... 57 
10.8 Potential Benefits of the Proposed Resear ch to Research Partic ipants and Others .......................................... ...... 59 
10.9 Importance of Know ledge to be Gained ..................................................................................... .............................. 60 
10.10 Data and Safety Monitoring Plan ......................................................................................... ................................... 60 
10.10.a Part A: Clinical  Monitoring Plan ...................................................................................... ................................. 60 
10.10.b Part B: Data  Monitoring Plan .......................................................................................... ................................. 61 
11.0 ClinicalTrials.gov Requirements  .............................................................................................................................. ..... 67 
12.0 References  .............................................................................................................................. ...................................... 68 
 
 
  
 
Principal Investigator: [CONTACT_70798], Grace, Hsiao-Wei                                                                                             A Pi[INVESTIGATOR_450777] 
 
[ADDRESS_574752] Protocol V5.0 6 May 2022 Abbreviation Glossary 
Adverse Event (AE)  – Any unfavorable and unintended diagnosis, sign (i ncluding laboratory finding), symptom or disease 
temporarily associated with the study intervention. 
Australian Canadian Hand OA Index (AUSCAN) scale1,2 – validated symptom and function  scale for hand osteoarthritis. 
Case Report Form (CRF)  – A printed, optical, or electronic (eCRF) do cument designed to record information about study 
participants. 
Center for Epi[INVESTIGATOR_6328] (CES-D)  3 – a validated measure of depression  
Code of Federal Regulations (CFR)  – An annual compi[INVESTIGATOR_450779]. 
Computerized Patient Record System (CPRS)  – a Veterans Health Information Systems and Technology Architecture 
(VistA) computer application. CPRS enables providers to en ter, review, and continuously update all the information 
connected with any patient. With CPRS, providers can or der lab tests, medications, diets, radiology tests and 
procedures, record a patient’s allergies or adverse reaction s to medications, request and track consults, enter progress 
notes, diagnoses, and treatments for each  encounter, and enter discharge summaries. In addition, CPRS supports clinical 
decision-making and enables review and analysis of patient data. 
Conflict of Interest (COI)  – A conflict of interest occurs when individuals  involved with the conduc t, reporting, oversight, 
or review of research also have financial or other intere sts that may be affected by [CONTACT_450812]. 
Consolidated Standards of Reporting Trials (CONSORT)  – This encompasses various initiatives developed by [CONTACT_450813].   
The CONSORT Statement  – This is the main product of CONSORT.  It is an evidence-based, minimum set of 
recommendations for reporting randomized trials.[ADDRESS_574753] items focus on reporting how the trial was designed, 
analyzed, and interpreted; the flow diagram displays the progress of all participants through the trial. 
Disabilities of the Arm, Shoulder, and Hand (DASH)5 – developed in the 1990’s, it is a patient-reported outcome 
measure for musculoskeletal conditions and injuries a ffecting the upper limb – the arm, shoulder, or hand.  
Food and Drug Administration (FDA)  – An agency within the U.S. Department of Health and Human Services (DHHS), 
responsible for protecting public health by [CONTACT_450814], efficacy, and security of human and veterinary drugs, 
biological products, medical devices, nation’s food s upply, cosmetics, and products that emit radiation. 
Good Clinical Practice (GCP)  – Section [ADDRESS_574754] (HIPAA) Privacy Rule  – Public Law 104-[ADDRESS_574755] certain health care 
 
Principal Investigator: [CONTACT_70798], Grace, Hsiao-Wei                                                                                             A Pi[INVESTIGATOR_450777] 
 
[ADDRESS_574756] Protocol V5.0 6 May 2022 groups, organizations, or businesses, called covered entities  under the Rule, use and disclose individually identifiable 
health information known as protected health information (PHI).  Title II also establishes that covered entities ensure the 
security and privacy of PHI. 
Institutional Review Board (IRB) – An independent body consisting of medica l, scientific, and non-scientific members 
whose responsibility it is to ensure the protection of the ri ghts, safety, and well-being of human subjects involved in a 
trial by, among other things, reviewing, approving, and provid ing continuing review of trials, protocols and amendments, 
and of the methods and materials to be used to obtain and document the informed consent of trial participants. 
International Conference on Harmonization (ICH)  – An international collaboration  between the [LOCATION_002], the 
European Union and Japan to harmonize the testing require ments of pharmaceutical products intended for human use. 
ICH's mission is to achieve greater harmonization worldwide to ensure that safe, effective, and high quality medicines 
are developed and registered in the most resource-e fficient manner. Harmonization is achieved through the 
development of ICH Guidelines via a process of scientific consensus with regulatory and industry experts working side-
by-side. 
International Physical Activity Questionnaire (iPAQ)6 – a validated questionnaire that  asks questions about physical 
activity 
Investigational New Drug Application (IND)/ Investigational Device  Exemptions (IDE)  – An IND is the means through 
which the Food and Drug Administration (FDA) grants the sponsor permission to administer an investigational drug or 
biological product to humans. Such authorization must be se cured prior to interstate shipment and administration of 
any new drug or biological product that is not the subjec t of an approved New Drug Application or Biologics/Product 
License Application (21 CFR 312). 
An IDE allows the investigational device to be used in a clin ical trial to collect safety and effectiveness data for human 
use (21 CFR 812). 
Manual of Operating Procedures (MOOP)/Manual of Procedures (MOP)  – A “cookbook” that tr anslates the protocol 
into a set of operational procedures to guide study conduc t. A MOOP/MOP is developed to facilitate consistency in 
protocol implementation and data collection across study participants and clinical sites. 
Michael E. DeBakey Veterans Affairs Medical Center (MEDVAMC)  – The main veterans’ medical center in Houston and 
the setting where this study will take place. 
National Archives and Records Administration (NARA)  – guidance for the VA on how to manage records. 
National Institute of Arthritis and Musc uloskeletal and Skin Diseases (NIAMS)  – the funding body for this study.  
Not Applicable (NA)  –When recording data on a study form, if the in formation is not applicable, then the acronym NA 
should be used to fill out the field. 
Not Available (NAV)  – When recording data on a study form, if the information is not available, then the acronym NAV 
should be used to fill out the field. 
 
Principal Investigator: [CONTACT_70798], Grace, Hsiao-Wei                                                                                             A Pi[INVESTIGATOR_450777] 
 
[ADDRESS_574757] Protocol V5.0 6 May 2022 Not Done (ND)  – When recording data on a study form, if the evaluation required for a field is not done, then the 
acronym ND should be used to fill out the field. 
Occupational Therapi[INVESTIGATOR_541] (OT)  – This is our study staff who provides occupati onal therapy to our participants and fits the 
participants with either the hand-based traction orthosis or the resting orthosis.   
Office for Human Resear ch Protection (OHRP)  – A federal government agency with in the Department of Health and 
Human Services (DHHS) charged with the protection of human subjects participating in government-supported research. 
The OHRP issues assurances to institut ions reviewing human subjects research and oversees compliance of regulatory 
guidelines by [CONTACT_450815]. 
Osteoarthritis (OA)  – a common form of joint disease that most often affects the hands, hips, knees and feet and is the 
subject of study in this clinical trial.  
Posterior-Anterior (PA)  – Describes the direction that a radiograph is acquired. 
Principal Investigator (PI)  – The individual with primary responsibility for achieving the technical success of the project, 
while also complying with the financial rules and requirements , administrative policies, and regulations associated with a 
grant or award. Although Principal Investigators may have ad ministrative staff to assist them with the management of 
project funds, the ultimate responsibility for the management of the research project rests with the Principal 
Investigator. 
Proof of Concept (POC)  – Describes the radiographs that evaluate the cha nge in joint space that occurs with application 
of the traction and the resting orthoses.  
Quality Control (QC)  – The internal operational techniques and activities undertaken within the quality assurance 
system to verify that the requirements for quality of trial re lated activities have been fulfilled (e.g., data and form 
checks, monitoring by [CONTACT_464], routin e reports, correction actions, etc.). 
Research Coordinator (RC)  – An individual that handles the administrative  and day-to-day responsibilities of a clinical 
trial. This person may collect or review data  before it is entered in the study database. 
Safety Monitoring Plan (SMP)  – A plan that outlines the oversight of a clinical trial. 
Safety Officer (SO)  - The Safety Officer is an independent individual, usually a clinician, who performs data and safety 
monitoring activities in low-risk, single-site clinical st udies. The Safety Officer advises the NIAMS Program Director 
regarding participant safety, scientific in tegrity and ethical conduct of a study. 
Serious Adverse Event (SAE)  – Any untoward medical o ccurrence that results in: 
 death 
 is life threatening 
 requires or prolongs hospi[INVESTIGATOR_059] 
 causes persistent or signifi cant disability/incapacity 
 
Principal Investigator: [CONTACT_70798], Grace, Hsiao-Wei                                                                                             A Pi[INVESTIGATOR_450777] 
 
[ADDRESS_574758] Protocol V5.0 6 May 2022  results in congenital anomalies/birth defects 
 represents other significant hazards or potentially serious harm to research 
participants or others 
Standard Operating Procedure (SOPs)  – Detailed written instructions to achieve uniformity of the performance of a 
specific function acro ss studies and patients at an individual site. 
Unknown (UNK) - When recording data on a study form, if the in formation is unknown, then the abbreviation UNK 
should be used to fill out the field. 
Veterans Administration (VA)  – Health care system that se rves [LOCATION_002] veterans. 
Veterans Health Administration Records Control Schedule 10-1 (VHA RCS 10-1)  – Document which provides guidance 
for VA research on how long to retain and how to properly dispose of data. 
 Visual Analog Scale (VAS)  – a psychometric response scale which can be used  in questionnaires.  It is a continuous scale. 
  
 
Principal Investigator: [CONTACT_70798], Grace, Hsiao-Wei                                                                                             A Pi[INVESTIGATOR_450777] 
 
[ADDRESS_574759] Protocol V5.0 6 May 2022 STATEMENT OF COMPLIANCE 
This trial will be carried out in  accordance with International Conference on  Harmonization Good Clinical Practice (ICH 
GCP) and the following:  
 
• [LOCATION_002] (US) Code of Federal Regulations (CFR) applicable to clinical studi es (45 CFR Part 46, 21 CFR 
Part 50, 21 CFR Part 56, 21 CFR Part 312, and/or 21 CFR Part 812)  
 
National Institutes of Health (NIH)-fund ed investigators and clinical trial site staff who are responsible for the conduct, 
management, or oversight of NIH-funded clinical trials have completed Human Subjects Protection and ICH GCP 
Training.  The protocol, informed consent form(s), recruitment material s, and all participant materials will be submitted to the 
Institutional Review Board (IRB) for review and approval.  A pproval of both the protocol and the consent form must be 
obtained before any participant is enrolled.  Any amendment to the protocol will require review and approval by [CONTACT_242206].  In additi on, all changes to the consent form will be IRB-approved; a 
determination will be made regarding whether a new consent needs to be obtained from participants who provided 
consent, using a previously  approved consent form. 
 
 
  
 
Principal Investigator: [CONTACT_70798], Grace, Hsiao-Wei                                                                                             A Pi[INVESTIGATOR_450777] 
 
[ADDRESS_574760] Protocol V5.0 6 May 2022 DATA COLLECTION INFRASTRUCTURE / SIGNIFICANT STATEMENT OF ATTESTATION  
Most study data will be collected and managed using the REDCa p electronic data capture tools, designed to comply with 
HIPAA regulations.7,[ADDRESS_574761] access this tool using a comp uter with a stable internet connection.  It is designed to 
support data capture for research studies from anywhere in the world with secure web authentication, data logging, and 
Secure Sockets Layer (SSL) encryption.7  It provides: 1) an intuitive interface for validated data entry  2) audit trails  for 
tracking data manipulation and export procedures 3) automated export procedures  for seamless data downloads to 
common statistical packages, an essential feature for data back-up and 4) user-f riendly procedures for importing data 
from external sources.[ADDRESS_574762] protected desktop or laptop 
computer with a sufficient power source (either with sufficien t charge in the battery or co nnected to a wall outlet) will 
be used to access REDCap to assure proper data capture, particularly at each in person visit but also with every instance 
of data entry.   
All study related electronic data will be stored on R0 2HOUFPC001.r02.med.va.gov , and will be accessible through 
"\\r02.med.va.gov\Research\HOU\Production\Da ta\Housrd\Research\Lo_G_Hand_Study_H-[ZIP_CODE] ".  This folder will 
be housed on a secured server within the MEDVAMC network, which is part of the VA nationwide network. Hence, our 
computers conform to VA security polic ies and standards. These po licies and standards include but are not limited to 
strong passwords, locking screensavers, up-to-date anti-virus protection, and storage of sensitive patient information 
stored on VA servers on the VA network. The servers are pr otected by [CONTACT_450816].  All servers are backed 
up daily to ensure data protection. Only study personnel,  NIH personnel, or IRB personnel who require information 
regarding the study will be given access to data on this folder. 
 
Study staff will collect data for use in this study only as  specified above.  Information will only be accessed as 
needed to schedule appointments, collect study-relevant data, and run data related analyses.   
 
All staff members involved in the conduct of this study ar e informed about their obligations in meeting the above 
commitments. 
 
1.0  Executive Summary 
Hand osteoarthritis (OA) is a common problem occu rring between 37-44% of the general population,[ADDRESS_574763] rheumatoid arthritis.10,11  To date, few therapi[INVESTIGATOR_450780]; a nd most are only based on expert opi[INVESTIGATOR_1649].12-[ADDRESS_574764] of care includes 
oral analgesics, oral/topi[INVESTIGATOR_35791] (if not contra-indicated), a thermal modality, orthoses, activity modification / joint 
protection education, and range of motion exercises.12-14  Although nodal hand OA has tr aditionally not been viewed as a 
biomechanically driven the disease, there is growing eviden ce that indeed it is, including that collateral ligaments 
 
Principal Investigator: [CONTACT_70798], Grace, Hsiao-Wei                                                                                             A Pi[INVESTIGATOR_450777] 
 
[ADDRESS_574765] Protocol V5.0 6 May 2022 surrounding a joint are consistently damaged,15,16 which may lead to altered joint biomechanics.  Highlighting the 
importance of this finding, other pathology is observed near these damaged ligaments in regions where features of OA 
tend to be found.15-18  
For OA in the knee, a disease long known to be biomechanically driven,19-27 surgical distraction is a novel treatment 
where peri-articular external pi[INVESTIGATOR_450781], providing intra-articular negative 
pressure, and increasing the joint space.28 Distraction has been used successfully to treat people awaiting knee total 
knee arthroplasty, reducing pain, allowing growth of new ar ticular cartilage, and ultimately delaying and sometimes 
obviating the need for arthroplasty.28-33  Although an impressive observation, it is important to note serious 
complications associated with this intervention, including a 10% rate of pulmonary emboli despi[INVESTIGATOR_450782] 85% rate of pin site infection [ADDRESS_574766] 3 joints affe cted by [CONTACT_450817] (DIP) nodal hand OA, with at least one joint with 
frequent pain.  The hand with the DIPs with the greatest seve rity level of pain will be eligible for randomization into (1) 
standard of care or (2) traction plus standard of care.  If results from this study support feasibility of implementing 
traction using finger trap splints, proof of concept that finger  traps provide traction, as well as symptomatic / functional 
and structural improvement with traction therapy, we will use findings from this st udy to inform a larger R01 study that 
can be adequately powered to address efficacy and clinical utility of this treatment.    
  
 
Principal Investigator: [CONTACT_70798], Grace, Hsiao-Wei                                                                                             A Pi[INVESTIGATOR_450777] 
 
[ADDRESS_574767] Protocol V5.0 6 May 2022 1.1 Schedule of Activities (SoA) 
The schedule below is what is  planned for our participants.  
 
Procedures 
Screening Visit -  Day -30 to -1 
Enrollment/Baseline Visit 1, Day 1  +/-7 days 
Reminder Visit 1, Day 7  +/-3 days 
Study Visit 2, Day 14 +/- 7 days 
Reminder Visit 2, Day 21  +/-3 days 
Study Visit 3, Day 28 +/- 7 days 
Reminder Visit 3, Day 35  +/-3 days 
Reminder Visit 4, Day 42 +/-3 days 
Reminder Visit 5, Day 49  +/-3 days 
Reminder Visit 6, Day 56  +/-3 days 
Reminder Visit 7, Day 63  +/-3 days 
Reminder Visit 8, Day 70  +/-3 days 
Reminder Visit 9, Day 77  +/-3 days 
Study Visit 4, Day 84 +/- 14 days 
Reminder Visit 10, Day 91  +/-3 days 
Reminder Visit 11, Day 98  +/-3 days 
Reminder Visit 12, Day 105  +/-3 days 
Reminder Visit 13, Day 112  +/-3 days 
Reminder Visit 14, Day 119  +/-3 days Reminder Visit 15, Day 126  +/-3 days 
Reminder Visit 16, Day 133  +/-3 days 
Reminder Visit 17, Day 140  +/-3 days 
Reminder Visit 18, Day 147  +/-3 days 
Reminder Visit 19, Day 154  +/-3 days 
Reminder Visit 29, Day 161  +/-3 days 
Final Study Visit, Day 168 +/- [ADDRESS_574768] symptomatic DIP joint c    X                       X  
Weekly Reminders (telephone, text, or email)   X  X  X X X X X X X  X X X X X X X X X X X  
Adverse Event and Review   X X X X X X X X X X X X X X X X X X X X X X X X 
F i n a l  V i s i t  A s s e s s m e n t  Q u e s t i o n s                           X  
a Only for those being screened for MRI 
b Only for those of childbearing age who are women 
c Only for a selected group of 10 participants 
 
Table 1. Schedule of Activities.   
 
Principal Investigator: [CONTACT_70798], Grace, Hsiao-Wei                                                                                             A Pi[INVESTIGATOR_450783] 
 
[ADDRESS_574769] 
beyond articular cartilage.  Panel B  is a schematic providing greater detail of the true 
anatomic relationship of these structures where the positi on of the collateral ligaments 
on the proximal phalanx end is attached in a pi t (P) further away from the joint, creating a 
unique spatial geometry in the way the ligament and bone interact.  Panel C  is an 
enlargement of the schematic in Panel  B.  This panel shows that there is enthesis 
fibrocartilage (EF), periosteal fibrocartilage (PF), and synovial fibrocartilage (SF) that 
meet to form the S ynovio-Entheseal Com plex (SEC). From McGona gle et al.  
2.0  Background and Significance 
2.1 Hand Osteoarthritis Is a Public Health Problem.   Hand osteoarthritis (OA) is a common problem occurring between 
37-44% of the general population,[ADDRESS_574770] rheumatoid arthritis.10,11  With aging of the general population, the burden of this disease is 
likely to increase.  Additionally, few therapi[INVESTIGATOR_450784]; and most are only 
based on expert opi[INVESTIGATOR_1649].12-14 Such therapi[INVESTIGATOR_450785], or al/topi[INVESTIGATOR_35791] (if not contra-indicated), 
thermal modalities, orthoses, activity modification / join t protection education, and range of motion exercises.12-[ADDRESS_574771] given the high prevalence of this 
debilitating disease.    
2.2 Nodal OA is a Phenotype of Hand Osteoarthritis . Within hand OA, there are multiple phenotypes, including thumb 
base OA, nodal (Heberden’s and Bouchard’s) OA involving the interphalangeal (IP) jo ints, and erosive OA.  The 
etiopathogenesis of these phenotypes are likely different.  In this study, our primary interest is in nodal OA.  Studies 
have shown that hand OA is symmetric and in women, is more likely to cluster by [CONTACT_450818] (i.e. involving multiple 
DIPs in the same hand) than by a ray (i.e. involving a DIP and a PIP in the same digit), although they also do cluster by 
[CONTACT_450819].34,35  For years, the prevailing thought regarding the underlying  etiology of this phenotype was driven by [CONTACT_450820], suggesting a genetic or systemic factor driving the disease and less likely a biomechanical factor.35   
2.3 Evidence of a Biomechanical Component to Hand Osteoarthritis .  In an effort to better understand nodal OA, in 
particular to identify the anatomic region where non-trau matic hand OA begins, Tan et al performed a cross-sectional 
study evaluating differences among joints with chronic nodal OA, 
early nodal OA, latent OA, and normal joints using magnetic 
resonance imaging (MRI).15  Tan et al found that joints with early and 
chronic nodal OA universally had some  irregularity of their collateral 
ligaments, whether it was thickening, increased signal, and/or 
disruption of the collateral ligaments.[ADDRESS_574772] to microdamage near the insertions, 
presumably resulting in inflammation (small red arrows) 
emanating from the ligament insertion sites. From McGonagle et al and Tan et al.  
 
Principal Investigator: [CONTACT_70798], Grace, Hsiao-Wei                                                                                             A Pi[INVESTIGATOR_450783] 
 
[ADDRESS_574773] patients with early and chronic 
OA, even when radiographs appeared normal and in ma ny instances where articular cartilage was preserved.16  There 
were 2 types of erosions.  The less common type is the one that is well described in OA, the central erosions that are 
also called “seagull-wing erosions”.16  More interestingly, the more common ty pe of erosions were peri-articular, often 
occurring adjacent to the collateral ligaments,16 again suggesting that ab erration of the collateral  ligaments might be an 
instigating phenomenon in nodal hand OA. The observation of  aberrant collateral ligaments  with associated edema and 
proximate erosions has led to the concept of the synovio-enthes eal complex (SEC) as seen in figure 2.  If pathology in 
nodal OA indeed begins with derangement of the collateral ligament, this supports a biomechanical component to nodal 
hand OA. 
2.4 Evidence that Biomechanics are Important in Knee Osteoarthritis.   There is substantial data to support that 
biomechanics are important in the pathophysiology of knee OA, with research showing that static and dynamic 
alignment are potent predictors of comp artment specific longitudinal progression,20,21,25 including that varus and valgus 
(i.e. bow legged and knock-kneed) alignment are associated with longitudinal medial and lateral tibiofemoral joint space narrowing 
respectively.  Also, bone marrow lesions, defined as 
increased signal within bone on intermediate weighted or T2 weighted fat suppressed images, have 
also been associated with longitudinal progression in 
a compartment specific manner where medial tibiofemoral bone marrow lesions are predictive of 
medial tibiofemoral joint space narrowing.
22,23  
Furthermore, meniscal derangement is also 
associated with longitudinal compartment specific 
progression.24  All taken together, the evidence for the central ro le of biomechanical factors in knee OA is strong. 
2.5 Distraction is a Treatment for Knee Osteoart hritis that Improves Structure and Symptoms. Distraction (figure 3) is a 
treatment where peri-articular external pi[INVESTIGATOR_450786], providing 
intra-articular negative pressure, and increasing the joint space.[ADDRESS_574774] ive.  There was an increase in the articular cartilage as Figure 3. This is a knee that has 
been distracted, where peri-
articular external pi[INVESTIGATOR_450787], providing 
intra-articular negative pressure 
and increasing the joint space.  
Taken from Wiegant et al.  
 
Principal Investigator: [CONTACT_70798], Grace, Hsiao-Wei                                                                                             A Pi[INVESTIGATOR_450783] 
 
[ADDRESS_574775] Protocol V5.0 6 May 2022 Figure 6. Fluoroscopic images of a 5th finger 
with nodal DIP OA.  Panel A was obtained 
without a finger trap applied.  Panel B was 
obtained with a finger trap applied. The red 
arrows highlight the increase in the DIP joint 
space with the fin ger tra p applied.   
measured by [CONTACT_450821] (figure 4).  
Furthermore, there was improvement in all domains of the WOMAC.[ADDRESS_574776]-traumatic OA rat model where the 
anterior cruciate ligament (ACL) was transected and 
the medial meniscus was resected, the benefits of distraction, compared with fixation (where the joint 
was immobilized but negative pressure was not 
applied) compared to no treatment was studied.
[ADDRESS_574777] osteophytes.
31 (See 
figure 5.) Microscopi[INVESTIGATOR_450788], lower levels of inflammatory 
markers in the serum and the less aberrant subchondral bone as 
measured by [CONTACT_84798]-CT and by [CONTACT_450822].[ADDRESS_574778] other treatments for knee OA.  
2.6 Adverse Events Associated with Distraction. Although results from distraction are impressive, providing both 
symptom and structural benefits, serious associated complications, including a 10% rate of pulmonary emboli despi[INVESTIGATOR_450789] 85% rate of pin site infection  28 limit widespread use of this treatment.  Nevertheless, this 
treatment provides an important proof of concept that unloading an osteoarthritic joint may allow structure and 
symptom improvement.    
2.7 Finger Traps May Provide Traction to Finger Joints Si milar to Distraction Without the Attendant Serious Adverse 
Events.  Using knee OA as a model in which to think about hand OA, a joint where a biomechanical role has long been 
evident, (IA4.) we speculate that finger traps might be an e ffective non-invasive method of applying traction in hand OA.  
A finger trap is an medical device, already FDA-approved, that provides non-invasive traction to proximate joints, cu rrently used as a treatment for distal 
radius fractures
37-[ADDRESS_574779] amount of articular cartilage damage on gross inspection 
after the animals were sacrificed.  Taken from Chen et al. 

 
Principal Investigator: [CONTACT_70798], Grace, Hsiao-Wei                                                                                             A Pi[INVESTIGATOR_450777] 
 
[ADDRESS_574780] for deep venous thrombosis, there is little risk for pul monary emboli related to their use.  Thus, finger traps may 
provide traction for hand OA without attendant seriou s adverse events associated with distraction.   
We performed fluoroscopy on one volunteer with nodal hand OA, with and without a finger trap applied (Figure 6).  
With a finger trap there was an increase in the DIP joint spac e, indicated by [CONTACT_450823] , as well as in all proximate 
joints.  We also assessed tolerability of the traction orthoses on four volunteers.  All were able to wear the orthoses for 
[ADDRESS_574781] is that the premise of this study is based on 
a novel idea that  nodal OA is a biomechanically driven disease (2.3), supported by [CONTACT_450824]. This unique perspective inspi[INVESTIGATOR_450790].  The second innovation is the use 
of knee OA as a model to consider hand OA which led us to consider the merits of  distraction, a unique treatment that 
has both symptom and structure benefits, in knee OA to hand OA .  The obstacles preventing wide-spread use of 
distraction in knee OA are potentially avoided by [CONTACT_450825].(2.7)  The 
final aspect of innovation is the use of finger traps, a non-invasive medical device currently used for other purposes, to 
provide traction, as a possible combined symp tom and structure treatment for nodal hand OA .  
  
 
Principal Investigator: [CONTACT_70798], Grace, Hsiao-Wei                                                                                             A Pi[INVESTIGATOR_450777] 
 
[ADDRESS_574782] issues 
related to creating the traction orthoses, ease/difficulty of  applying the intervention, comfort level while wearing the 
orthosis, hand pain, and compliance of wearing the orthosis .  At the final study visit, we will also ask whether 
participants plan to use the orthosis after completion of the study. 
Specific aim 2. Proof of concept .  For 10 participants, 5 participants in ea ch arm that are age and sex matched, at the 
two week follow up, we will obtain radiographs of the hand with  and without  orthoses applied to assess whether 
applying the traction orthosis results in  an increase in joint space width.   
Specific aim 3. Symptomatic and functional outcomes .  At baseline, 1 month, 3 months , and 6 months follow up, we will 
assess outcomes including the visual an alog scale (VAS) in the more symptomatic hand that includes the most 
symptomatic DIP joint (primary symptom outcome), the VAS pa in scale of the most painfu l DIP, the AUSCAN function 
subscale,1,2 the Functional Index for Hand Osteoarthritis (FIHOA),42 the Disabilities of the Arm, Shoulder, and Hand 
(DASH)5, the Functional Dexterity Test43, grip and pi[INVESTIGATOR_32261], and tenderness on joint palpation on all participants.44   
Specific aim 4. Imaging outcomes .  On all participants, we will obtain bilateral hand radiographs at baseline and at 6 
months to assess changes in Kellgren and Lawrence scores45 (primary structure outcome), joint space narrowing, and 
osteophyte scores,46 and Verbruggen-Veys 47 in the DIP joints.  On 5 participants in each treatment arm (age and sex 
matched), we will obtain high resolution  MRI imaging at week [ADDRESS_574783] of care treatment 
that includes a resting hand splint.  
 The primary symptom endpoint will be pain as assessed on a visual analog scale (VAS) in the more symptomatic hand that includes the most 
symptomatic DIP joint by [ADDRESS_574784] of care treatment for hand OA to establish efficacy of traction therapy.   
 This outcome measure has been recommended by [CONTACT_450826]: 
Design and conduct of clinical trials for hand osteoarthritis.
[ADDRESS_574785] of care treatment that The primary structure endpoint will 
be change in sum of the Kellgren and 
Lawrence score
45 of all DIPs in the 
hand that was braced over 24 weeks.   The use of radiographic 
imaging as a means of measuring structural 
outcome has been 
recommended by [CONTACT_450827]: [CONTACT_70798], Grace, Hsiao-Wei                                                                                             A Pi[INVESTIGATOR_450777] 
 
[ADDRESS_574786] Protocol V5.0 6 May 2022 OBJECTIVES ENDPOINTS JUSTIFICATION FOR 
ENDPOINTS 
includes a resting hand splint. 
 Recommendations: 
Design and conduct of 
clinical trials for hand 
osteoarthritis.[ADDRESS_574787] of care treatment for hand 
OA to further support efficacy of 
traction therapy.  These outcomes will include: 
 The Functional Index for 
Hand Osteoarthritis (FIHOA)
42 
 The Disabilities of Arm 
Shoulder and Hand (DASH)49-
51 
 The Functional Dexterity 
Test43  
 Grip strength  
 Pi[INVESTIGATOR_32261] 
 Tenderness on joint 
palpation.  
 As this is a pi[INVESTIGATOR_799], we are making an 
attempt to include other measures that might also be of relevance and may 
perhaps be more 
useful in the follow up study to this pi[INVESTIGATOR_2268].  
The secondary structure objectives are to assess whether traction therapy plus standard of care treatment for nodal OA reduces structural progression compared 
with standard of care treatment 
that includes a resting hand splint.  The secondary structure endpoints 
will be  change in sum of the 
following scores all DIPs in the hand that was braced over 24 weeks: 
 joint space narrowing 
 osteophyte scores 
 Verbruggen-Veys scores Although a 24 week 
follow up time period might be too short to see a difference in the treatment arms, it is 
worth a look at the 
different radiographic features of OA to see if 
 
Principal Investigator: [CONTACT_70798], Grace, Hsiao-Wei                                                                                             A Pi[INVESTIGATOR_450777] 
 
[ADDRESS_574788] Protocol V5.0 6 May 2022 OBJECTIVES ENDPOINTS JUSTIFICATION FOR 
ENDPOINTS 
they are different 
between the two 
treatment arms. 
Tertiary/Exploratory    
The tertiary / exploratory structure 
objective is to assess whether 
traction therapy plus standard of care treatment for nodal OA 
modifies features of OA seen on 
MRI more compared with standard of care treatment that includes a 
resting hand splint. The exploratory endpoints include 
measurement in the most 
symptomatic DIP:  
 collateral ligament thickening 
 enthesial bone marrow 
edema 
 erosions  
 
Because this is a pi[INVESTIGATOR_450791], we are only evaluating these 
changes on 5 people in each 
treatment arm.    Prior observational 
studies indicated that 
there is pathology in these structures 
visualized on MRI.
15,16,36  
Perhaps these might change over a shorter 
period of time than 
radiographs.  If there is a signal with these 
measures then we 
might include MRI for 
all participants for the 
follow up clinical trial.  
The tertiary / exploratory clinical 
assessment objective is to evaluate 
whether traction therapy plus 
standard of care treatment for 
nodal OA modifies visual appearance of Heberden’s nodes 
using photographs compared with 
standard of care treatment that includes a resting hand splint. Visual inspection of the digital 
photographs for differences in 
erythema of the most symptomatic 
DIPs. This is a low risk 
outcome measure.  
Although it is not 
currently viewed as a 
standard outcome measure, if we can 
show this is a useful 
outcome measure this might serve as 
preliminary evidence to 
use this in our follow 
up study. 
Table 2. Study Objectives, Endpoints, an d the Justification of those Endpoints. 
  
 
Principal Investigator: [CONTACT_70798], Grace, Hsiao-Wei                                                                                             A Pi[INVESTIGATOR_450777] 
 
[ADDRESS_574789] Protocol V5.0 6 May 2022 4.0  Study Design 
4.1 Overview of the Proposed Study.  This is a pi[INVESTIGATOR_450792] (n=40) of finger traction therapy 
in the treatment of nodal hand OA where the control arm will receive the standard of care and the treatment arm will 
additionally use a finger traction orthosis.   
4.2 Investigators/Co-Investigators/Collaborators/Consultants 
Grace Hsiao-Wei Lo, MD MSc.  Principal Investigator (PI) and Study Physician.   She is an Assistant Professor at Baylor 
College of Medicine (BCM) in the Sectio n of Immunology, Allergy, and Rheumato logy, and an Affiliate Member of the 
Center for Innovations in Quality, Effe ctiveness and Safety at the Michael E. DeBakey Veterans Affa irs Medical Center 
(MEDVAMC) and BCM.  She has a Master’s of Science in Epid emiology and has been studying OA for the last [ADDRESS_574790]. Lo has recently been awarded an R03 (AR069323) where she has recruited offspring of the Osteoarthritis 
Initiative, a large observational cohort study of osteoarthr itis to better understand risk factors of early OA.  The 
experience she has and will accumulate from the R03 will inform  the conduct of this proposed study.  Additionally, this 
study will recruit from the MEDVAMC, where she has had her rh eumatology clinical practice for the last [ADDRESS_574791].  Since joining the [LOCATION_001] Un iversity (NYU) faculty in 2006, he has initiated the largest 
registry and biorepository of North American patients with isolated hand OA, currently at N=160.  [CONTACT_450867] has 
agreed to be the site PI [INVESTIGATOR_8178] a second recruitment location at NYU/Langone as we have had difficulty recruiting for this 
clinical trial.  He has agreed to aim to recruit [ADDRESS_574792] to the [LOCATION_008] but maintains a 
Workers without Compensation (WOC) status  to continue work on our study.  She still meets with our team regularly via 
Zoom to assist with study related questions  and will assist in interpretation and report of our findings once we close the 
data for analysis.  She will liaise regul arly with the OT team at NYU to address any questions or concerns regarding 
fabrication or application of the orthoses. 
 
Principal Investigator: [CONTACT_70798], Grace, Hsiao-Wei                                                                                             A Pi[INVESTIGATOR_450777] 
 
[ADDRESS_574793] (OT).   He 
is an occupational therapi[INVESTIGATOR_450793] [ADDRESS_574794] (OT).  She is an occupational therapi[INVESTIGATOR_450794] 2009 and is the Supervisor of the hand therapy department 
at NYU Langone Orthopedic Center. Laura earned her Master ’s of Science in Occupational Therapy from [LOCATION_001] 
University and is a Certified Hand Therap ist (CHT). She holds a number of advance d certifications in several therapeutic 
techniques. Her areas of interest include complex splinting, and conditions of the upper extremity. She has published in 
the journal of hand therapy in the area of wrist propriocepti on as well as in an orthoped ic textbook on  the topic of 
rehabilitation of the shoulder post arthroplasty. Laura has presented at a number of NYU academic conferences and is 
an active member of the Rusk Strategic Pl an initiative.  For this project, at the NYU clinical site, she will supervise the 
fabrication and application of orthoses to participants of  this study, depending on the treatment group based on 
randomized.  She will liaise regularly with the OT team at BCM/VA with any questions or concerns regarding fabrication 
or application of the orthoses. 
Monica Seu, Co-investigator and Study Hand Occupational Therapi[INVESTIGATOR_541] (OT).  Monica is an occupational therapi[INVESTIGATOR_450795] 2000 and is the Hand Therapy Fellowship Coordinator at NYU Langone Orthopedic Center. 
Monica earned her Master’s of Science in Occupational Th erapy from Touro College and is a Certified Hand Therapi[INVESTIGATOR_541] 
(CHT). She holds a number of advanced ce rtifications in several therapeutic techniques. Her areas of interest include 
complex splinting, and conditions of the upper extremity. She has participated in a research project looking at 
instrument assisted mobilization in the treatment of de  Quervain’s and contributed to a chapter in Hand Clinics 
regarding the rehabilitation of patients with intrinsic musc le issues. Monica has presented at a number of NYU academic 
conferences and at AOTA.  For this project,  at the NYU clinical site, she will prov ide participants of this study with the 
standard of care for hand OA, including a thermal modality, jo int protection strategies, and range of motion exercises.  
Additionally, she will customize either a resting hand orthosis  or a traction hand orthosis , depending on the treatment 
group based on randomized. 
Peter Richardson, PhD. Co-investigator.   He is an Assistant Professor and seni or biostatistician in the Department of 
Medicine, Section of Health Services Research at BCM.  He also has an appointment at the IQuESt, at Baylor College of 
Medicine and the MEDVAMC and his office is housed in th e same Center as [CONTACT_435018].  [CONTACT_241940] will provide 
intellectual input on the overall design a nd execution of this study, statistical an alyses, and interpretation of results for 
this project.  Additionally, he will assist with issues related to quality control and quality assurance, generating 
randomization assignments for this study and assisting with  subgroup selection for proof of concept x-rays and the 
group that will receive MRIs.   
Timothy E. McAlindon, MD MPH.  Co-investigator.   He is Professor of Medicine and the Chief of the Division of 
Rheumatology at Tufts Medical Center.  From 2004 – 2009, [CONTACT_435018]  was faculty in his division.  She moved from [LOCATION_011] to 
Houston for personal reasons and was fortunate to find an ac ademic position at BCM and MEDVAMC.  Although [CONTACT_435018] 
changed institutions, Drs. Lo and McAlindon have continued to collaborate on many projects, including two R01 funded 
 
Principal Investigator: [CONTACT_70798], Grace, Hsiao-Wei                                                                                             A Pi[INVESTIGATOR_450777] 
 
[ADDRESS_574795] Protocol V5.0 6 May 2022 projects (AR054938 and AR060718) where he was PI [INVESTIGATOR_20196]. Lo wa s co-I.  Dr. McAlindon has an exemplary track record 
of conducting clinical trials in OA, including two trials eval uating vitamin D and intra-articular corticosteroids in the 
treatment of knee OA.  Further, he has an R01 (AR066378) st udying hand OA within the Osteoarthritis Initiative.  Dr. 
McAlindon will provide his expertise as a consultant in conduc ting OA clinical trials and general knowledge about hand 
OA to this project.  
Ida K. Haugen, MD PhD, Consultant.   [CONTACT_450868] is a rheumatologist at the Diakonhjemmet Hospi[INVESTIGATOR_307], Oslo, Norway and 
an accomplished hand OA researcher.   She is co-chair of  the Outcome Measures in Rheumatology (OMERACT) hand OA 
task force, co-chair of the development of EULAR classifica tion criteria for hand OA, and principal investigator [INVESTIGATOR_450796]-Hand Study.  She has extensive experience in evaluation of radiographic changes in hand 
osteoarthritis (OA), having undergone training in Kellgren-Lawrence,[ADDRESS_574796] 7 
years, she has scored more than 5000 cases in various No rwegian (Oslo hand OA cohort, the MUST study) and North-
American cohorts (Framingham and Osteoa rthritis Initiative). For this study, [CONTACT_450868] will provide batched readings 
for bilateral hand x-rays at baseline and 6 month follow up x-rays on all particip ants after all participant follow up is 
completed.  She will score paired Kellgren and Lawrence  grades, OARSI osteophyte an d joint space narrowing (JSN) 
scores, as well as the Verbruggen-Veys anatomic pha se score for each hand joint on each film.    
Andrew Grainger BMed Sci, BM BS, MRCP, FRCR, Collaborator.  [CONTACT_450869] is a radiologis t researcher and has been the 
consultant Musculoskeletal Radiologist to the Leeds Teaching  Hospi[INVESTIGATOR_450797]. Within the subspecialty he has particular interests in arthritis and sports imaging.  Drs. Grainger and Lo 
have a track record of collaboration, including two projec ts where they helped create semi-quantitative MRI based 
scoring systems for knee OA, the Bo ston Leeds Knee MRI Score (BLOKS)52 and the MRI Osteoarthritis Knee Score 
(MOAKS)53.  [CONTACT_450869] also collaborated with investigators Dr s. Tan and McGonagle who first described the aberrant 
collateral ligaments in hand OA.15,16,18,[ADDRESS_574797]. Lo in assessing eligibility, consent pa rticipants, and administer all the baseli ne and 1 month, 3 month, and 6 month 
questionnaires and exams blinded to th e treatment assignment.  Additionally, he/she will schedule appropriate 
radiographs and MRIs for study participan ts.  He/she will also be instrumental in creating and ultimately use the data 
management system for this study.    
Apoorva Patil, MBBS, DNB, Research Coordinator .  She joined NYU Langone Health in [ADDRESS_574798]. Samuels in assessing eligibility, consent participants, and administer all t he 
baseline and 1 month, 3 month, and 6 month questionnaires  and exams blinded to the treatment assignment.   
 
 
Principal Investigator: [CONTACT_70798], Grace, Hsiao-Wei                                                                                             A Pi[INVESTIGATOR_450777] 
 
[ADDRESS_574799] Participation Duration  
4.3.a Study Participation Duration: 
 Week -1 : Screening Visit (phone or email) (10 - 20 minut es) – Assess preliminary eligibility criteria  
 Week 0 : Eligibility/Baseline Visit (6 hours) – assess e ligibility criteria, obtain informed consent,  
all clinical outcome assessments, hand x-rays, prescreen ing assessment for MRI, hand therapi[INVESTIGATOR_450798]-
pharmacologic therapi[INVESTIGATOR_450799], randomization allocation, creation of hand orthosis based on 
randomization allocation. 
 Week 2 : Study Visit (0.5 – 3 hours) – All partic ipants: hand therapi[INVESTIGATOR_450800]; 
for selected 10 people: proof of concept X-rays, with a nd without orthoses in place AND MRI of one finger DIP 
 Week 4 : Study Visit (1.5 hours) – all clinical outcom e assessments, hand therapi[INVESTIGATOR_450800]. 
 Week 4 – 6 : Study Visit (0.5 hours) – MD visit if requested. 
 Week 12 : Study Visit (1 hour) – all clinical outcome assessments. 
 Week 24 : Study Visit (3-4 hours) – all clinical outcome asse ssments, bilateral hand X-rays, follow up MRI (if it  
was done at week 2. 
 
4.3.b Study Duration:  The estimated time between when study  opens for enrollment and final data collection occurs is 
18 months.  The estimated time between when study opens fo r enrollment and final data analysis is completed is 30 
months.   
 
Principal Investigator: [CONTACT_70798], Grace, Hsiao-Wei                                                                                             A Pi[INVESTIGATOR_450777] 
 
[ADDRESS_574800] will be the Women’s Health Clinic s, Geriatrics Clinics, and Pr imary Care Clinics.      
The MEDVAMC serves nearly 130,000 veterans an d hand OA prevalence is between 37 – 44%.[ADDRESS_574801] symptomatic nodal OA, so this prevalence will be lower with estimates from Framingham between 8-16% of 
participants.[ADDRESS_574802] 
a 1% recruitment rate.   
To address possible sex differences in the use and efficacy of the intervention, we will make a concerted effort to ensure 
the study sample is similar to the larger hand OA population in terms of gender.  To operationalize this 
recommendation, we base our target recruitment on Framingham data where age-standardized prevalence of 
symptomatic hand OA in women and men respectively were 15.9% and 8.2%9.  Thus, we will oversample women in our 
VA at a ratio of 2:1, women : men to replicate a similar gender distribution to increase the generalizability of our 
findings.  Our primary strategy for oversampling women is that  we will use patient lists from the Women’s Health Clinics 
to identify women who have upcoming visits to at our VA wh o are more likely to have hand OA.  This will include women 
who have had hand x-rays that show evidence of hand OA  and all who are over [ADDRESS_574803] with, our Research Coordinator, Michael Strayhorn, will 
administer the “ Telephone Screening Survey ,” on RedCap.  However as these people will not yet have consented none 
of these responses will be saved on RedCap. If they pass the survey as possibly being eligible, Michael will maintain their 
names and contact [CONTACT_158865] a se parate Excel Spreadsheet entitled “ PreEnrollment Tracker ” (Appendix G ) and 
invite them to attend an in-person eligibility evaluation visit.   At the beginning of the visit, our Research Coordinator will 
obtain informed consent to conduct study  activities.  Once that is complete d, then the “Screening Survey” will be 
administered at which time the information can and will be saved and stored on RedCap.    
The objective of performing the pre-screening process is to reduce the number of study applications who later are found 
to be ineligible.  Pre-screening will occur in on the telepho ne where a set of questions will be administered to vet out 
 
Principal Investigator: [CONTACT_70798], Grace, Hsiao-Wei                                                                                             A Pi[INVESTIGATOR_450777] 
 
[ADDRESS_574804]. Lo will assess eligibility for the trial by [CONTACT_450828].   
These responses will be recorded on RedCap under “ Eligibility Survey .”  Additionally, participants who are deemed 
eligible will be asked if they are in terested in enrollin g in the study.  
 
We anticipate that we may need to sc reen upwards of [ADDRESS_574805] of how ma ny participants we will be ab le to screen and recruit.   
 
We will keep track of all individuals evalua ted for study eligibility in the form of a Screening Log .  This will include the 
following information: 
 Potential participant initials 
 Study ID number (Screening number) 
 Age 
 Sex 
 Race 
 Ethnicity 
 Screening date 
 Eligibility Status 
o Eligible for study participation (Y/N) 
o Date enrolled 
o If not eligible, provide reason 
o If refused consent, provide reason 
 
5.[ADDRESS_574806] participant’s 
last study visit has occurred.   
5.3 Inclusion/Exclusion Criteria.   
Inclusion Criteria 
- Enrolled to receive medical care at the Michael E. DeBakey VA Medical Center  
- At least 3 joints affected by [CONTACT_450817] (DIP) nodal hand OA 
 - DIP nodal hand OA will be defined as Heberden’s nodes on physical exam.   - Sufficiently severe frequent pain of at least one DIP 
 - Frequent pain: pain on most days of the month for at least one month in the last year.   
 
Principal Investigator: [CONTACT_70798], Grace, Hsiao-Wei                                                                                             A Pi[INVESTIGATOR_450777] 
 
[ADDRESS_574807] Protocol V5.0 6 May 2022  - Minimum VAS pain severity of 40 on a 0 – 100 scale 
Exclusion criteria  
- History or current inflammatory arthritides  
 (examples: gout, psoriatic arthritis, and rheumatoid arthritis) - Prior surgery on the DIP joints 
- Planned surgery for the DIP joints 
- Pregnancy 
 
Inclusion of Women and Minorities.  Hand OA affects both men and women and all races and ethnicities.  All will be 
welcomed into this study.  It would be interesting to see if there seems to be a greater or lesser effect of the treatment 
in any of these groups.  Therefore, women and minorities w ill be included in this study.  We have projected the break-
down of numbers based on the overall impression of the ra cial and ethnic make-up of patients at the Michael E. 
DeBakey VA Medical Center (MEDVAMC) and taking into acco unt our plan to oversample women compared to women 
to replicate the gender distribution that occurs in the ge neral community.  Although in general, there are more men 
than women who are veterans, there are more women who have hand OA and women tend to participate more in clinical trials than men.  Due to our pl an to over-recruit women, we expect to recruit more women than men at a ratio of 
2:1.  Also at the MEDVAMC, African Americans and Latinos ma ke up a substantial portion of this population.  Thus we 
expect that each will likely represent about 15% of the enro lled participants.  The pattern of enrollment into this study 
will help inform enrollment targets for the expected follow up R01.    
 Inclusion of Children.  Because children are not part of our target populat ion of interest because they don’t tend to have 
hand OA and because they are not eligible to be veterans, children will be excluded from this study. 
 Eligibility Assessment . People who pass the pre-screen process will be scheduled for an in-person screening visit at the 
MEDVAMC in the Research Commons space.   At that visit, the research coordinator will meet with the participant 
candidate.  [CONTACT_435018] will then assess for eligibility for the tria l by [CONTACT_450829].  Additionally, participants who are deemed eligible w ill be asked if they are interest ed in enrolling in the study. 
 
5.4 Screening Failures. 
Screen failures are defined as participants who consent to participate in the clinical trial but are not subsequently 
randomly assigned to the study intervention or entered in th e study. A minimal set of screen failure information is 
required to ensure transparent reporting of  screen failure participants, to meet the Consolidated Standards of Reporting 
Trials (CONSORT) publishing requirements and to respond to que ries from regulatory author ities. Minimal information 
includes demography, screen failure details, eligibili ty criteria, and any serious adverse event (SAE). 
 Individuals who do not meet the criteria  for participation in this trial (screen  failure) because of insufficient pain, 
insufficient number of joints involved, pregnancy plans or status, or surgical plans ma y be rescreened. Rescreened 
participants should be assigned the same part icipant number as for the initial screening. 
 
5.5 Retention/Adherence Strategies .  Although hand OA is common,
[ADDRESS_574808] 
 
Principal Investigator: [CONTACT_70798], Grace, Hsiao-Wei                                                                                             A Pi[INVESTIGATOR_450777] 
 
[ADDRESS_574809] with 
the participants.   
 
  
 
  
 
Principal Investigator: [CONTACT_70798], Grace, Hsiao-Wei                                                                                             A Pi[INVESTIGATOR_450777] 
 
[ADDRESS_574810] Protocol V5.0 6 May 2022  
6.0 Study Intervention 
6.1 Consenti ng Process . All participants interested in  enrolling in the study will be given a copy of the MEDVAMC/BCM 
approved consent form.  Our research coordinator will review  the contents of the consent form with the participant, 
allowing the participant to ask any questions or express any concerns that emanate from that discussion.  Once all 
questions or concerns have been discussed and addressed, if  the participant still wishes to participate in the study, 
he/she will sign the consent form.  The original will be retain ed by [CONTACT_134639] a copy will be given to the 
participant.  There will be information in the consent form explicitly stating that participation in this research study is 
voluntary and that he/she may withdraw consent at any time without penalty.   
6.[ADDRESS_574811]. Richardson will use a macro in SAS that uses CALL RA NUNI and PROC PLAN to generate permuted blocks of 
randomization stratified by [CONTACT_4321].   
 He will create a designation of group A v. group B, without knowing which group represents the 
intervention and the control.   
 He will use block sizes of [ADDRESS_574812] participant of the 
study, our OT, Kimberly Goldie Staines will flip a coin to assign whether treatment “A” represent traction orthosis or 
standard of care.  She will keep this designation secret  and will not share this designation with study staff or 
participants.  Only our OT will be unb linded to treatment allocation.  Opaque storage bags will be provided to the 
participants to store their orthoses.  Our OT will make a specific point to tell the participants that they must store their 
orthoses in opaque bags when interacting with study staff.   Masking will be maintained through the course of the study, 
during data collection, including when ra diographs and MRIs are read and primary analyses are performed.  Only when 
all primary data analyses are completed will our OT reveal  which group is treatment “A ” and unmask the treatment 
allocation.   
Although we will make every effort to maintain blinding, it may be imperfect, where our research coordinator may 
accidentally have the treatment allocation revealed to him, by [CONTACT_450830]/she received.  Sh ould this happen, , this will be viewed as a protocol deviation.  Additionally, 
 
Principal Investigator: [CONTACT_70798], Grace, Hsiao-Wei                                                                                             A Pi[INVESTIGATOR_450777] 
 
[ADDRESS_574813] our alternate research coordinator who is still blinded, administer the treatment outcomes at the 
subsequent follow up visits.   
 Should the IRB, KAI, and/or our Safety Officer indicate a need  to unblind the study prior to th e end of data collection, [CONTACT_450870] must confirm the need to unblind the study.  Appropriate concerns that could be raised by [CONTACT_450831] d in the study.  [CONTACT_435018] will instruct our OT 
to reveal which group is treatment “A” to our study statisti cian, [CONTACT_450871], breaking the study blind.  All 
intentional and unintentional blindi ng will be reported to the IRB, KAI and our Safety Officer.    
 
6.[ADDRESS_574814] of care includes oral analgesi cs, oral/topi[INVESTIGATOR_35791] (if not contra-indicated), a 
thermal modality, activity modification / joint prot ection education, and range of motion exercises.12-[ADDRESS_574815] resting hand orthosis.   
If participants are still symptomatic by [CONTACT_450832], he /she will be offered a clinic visit with the study physician, 
[CONTACT_450872], who will assess whether medications are ne eded, including topi[INVESTIGATOR_199]/or oral analgesics.  
Our OT will create a standard customized hand-based resting orthosis.  
She will ask the participants to do the following:  
 Please answer the relevant questions in your daily log book. 
o [At that time, a log book will be given to the pa rticipant and the entries they will be asked to 
complete will be reviewed.] 
 Apply the orthosis every night for 30 - 60 minutes before going to bed.  
 Remove the orthosis every morning 30 – 60 minutes after awakening.   
 Please continue this schedule fo r the full [ADDRESS_574816] difficulty donning and/or removing the orthoses, the participants will be instructed to contact 
[CONTACT_450833].  A specif ic effort will be made to rein force these points during the 
scheduled in clinic visits scheduled for weeks 2 and 4.      All participants will be given an opaque bag in  which to carry their orthosis.  They will be told that they should use this 
bag at all times and that the only study staff who sh ould be allowed to open the bag will be our OT. 
 
 
Principal Investigator: [CONTACT_70798], Grace, Hsiao-Wei                                                                                             A Pi[INVESTIGATOR_450783] 
 
[ADDRESS_574817] materials 
available in the Occupational Therapy Clinic.  This will involve the use of a 
1/8 inch low stretch and low memory material (e.g. Manosplint 
Wisconsin or Performance Health Polyflex).  Our OT will draw a pattern for the orthosis at 1cm around the hand of interest, stoppi[INVESTIGATOR_450801].  The center of the thumb flap will be cut out to form a thumb hole component for proxim al stabilization of the orthosis.  
Our OT will then mold the orthosis  to the volar hand with care to 
accommodate for palmar arches and to exte nd all fingers to a comfort position.  Our OT will then flare the proximal edge 
of the orthosis to limit pressure on the volar forearm soft ti ssue.  The strappi[INVESTIGATOR_450802].  Soft padding will be added to the orthosis under the 
phalanges for comfort.   
The traction orthosis is identical to the resting hand orthosis with the exception that there is an addition of finger traps 
that will be applied to the orthosis.  The finger traps used in this study will be manufactured by [CONTACT_450834], 
Inc (ISI).   Finger traps have already received FDA approval under the Code of Federal Regulations, Title 21, Volume 8 
(21CFR890.5925), Revised April 2016.   
 Title 21 – Food and Drugs Chapter 1 – Food and Drug Administration, Department of Health and Human Services Subchapter H – Medical Devices 
Part 890 – Physical Medicine Devices 
Subpart F – Physical Medicine Therapeutic Devices Sec. 890.5925  Traction Accessory  (a) Identification. A traction accessory is a nonpowered accesso ry device intended for medical purposes to be used with 
powered traction equipment to aid in exerting therapeutic pulling forces on the patient's body. This generic type of 
device includes the pulley, strap, head halter, and pelvic belt.  (b) Classification. Class I (general controls). The device is exempt from the premarket notification procedures in subpart 
E of part [ADDRESS_574818] to the limitations in 890.9. The device is also exempt from the current good 
manufacturing practice requirements of the quality system regula tion in part 820 of this chapter, with the exception of 
820.180, regarding general requirement s concerning records and 820. 198, regarding complaint files. 
 On the FDA website, there were no MedWatch complaints related to finger traps.   
 
Principal Investigator: [CONTACT_70798], Grace, Hsiao-Wei                                                                                             A Pi[INVESTIGATOR_450777] 
 
[ADDRESS_574819] difficulty donning and/or removing the orthoses, the partic ipants will be instructed to 
contact [CONTACT_450833].  A specific effort will be made to  reinforce these points during 
the scheduled in clinic visits scheduled for weeks 2 and 4.     
 
She will ask the participants to do the following:  
 Please answer the relevant questions in your daily log book. 
o [At that time, a log book will be given to the pa rticipant and the entries they will be asked to 
complete will be reviewed.] 
 Wear the full orthosis with finger traps in place ev ery night for 30 - 60 minutes before going to bed.  
 Wear the full orthosis with finger traps in place every morning after awakening for 30 - 60 minutes.   
 At night, between the two wear periods, please remove the finger traps and just wear the remainder of 
the orthosis.   
 Please continue this schedule fo r the full [ADDRESS_574820] symptomatic DIP will be fitted with a finger trap.  Ad ditionally, our OT will also ask the participant if there are 
other joints which he/she would like to also be fitted with a finger trap.  We will have a variety of sizes of finger traps 
available at the time of fitting.  Each finger that will be fi tted with a trap will be sized for an appropriately sized finger 
trap that will be snug but easily removed by [CONTACT_2299].    Using a heat gun, our OT will heat and roll a slot at the distal edge of the orthosis to accommodate the center of each of 
the finger traps.  Then, with each finger trap applied, the end of the traction device loop will be marked on the posterior 
surface of the orthosis.  Our OT will perforate a hole in the or thosis at the end of the traction device length and insert a 
rubber band post upon which the loop of the finger trap will be  applied. A Velcro attachment will be applied to maintain 
appropriate tension of the finger traps.  Padding will be plac ed over the band after attach ment on the volar orthosis 
surface.  
 
Principal Investigator: [CONTACT_70798], Grace, Hsiao-Wei                                                                                             A Pi[INVESTIGATOR_450777] 
 
[ADDRESS_574821] consented into the study at the beginning of the screening visit are all considered to be 
enrolled.  All participants who meet inclusion criteria, ar e randomized into a treatment a llocation group, and receive 
their treatment will be included in the a-priori analyses  for Aim 3 and for the radiographic findings for Aim 4.  
 
6.7 Opportunity for a Doctor’s Visit. 
If a participant is still symptomatic by [CONTACT_68069] 4 visit, he/she  will be offered a clinic visit with the study physician, [CONTACT_450873], who will assess whether medications are needed, in cluding topi[INVESTIGATOR_199]/or oral analgesics/NSAIDs (if not 
contra-indicated). 
 6.8 Feasibility of Implementing a Finger Traction Orthosis.   Our OT will track ease/difficulty of creating customized 
traction orthoses.  All participants wearing traction and trad itional orthoses will be asked to keep a daily log of when 
they apply and remove the orthoses, comfort level of the or thoses, ease/difficulty of do nning the orthoses, how well 
they like the orthoses, and overall hand pa in using visual analog scales (VAS), prov iding scores from [ADDRESS_574822] a difference to support 
feasibility and proof of concept in this pi[INVESTIGATOR_799].  If we can prove efficacy of this treatment in those who are more 
symptomatic, then we can perform follow up studies that target  those with milder disease.  There will be a potential for 
confounding due to lack of blinding of all study personnel.  We will attempt to minimize this risk of confounding using 
multiple strategies.  We will limit the treatment allocation information to the OT only.  Every effort will be made to 
maintain blinding of the PI, statistician and the research coordi nator.  When we notify participants of their clinic visits, 
we will remind them to refrain from telling anyone which orth oses they were given.  We will provide opaque bags to 
carry the orthoses to help maintain b linding.  The research coordinator will be the person performing the clinical 
assessments and will not be performing the statistical analys es for the study, decreasing the risk of confounding due to 
 
Principal Investigator: [CONTACT_70798], Grace, Hsiao-Wei                                                                                             A Pi[INVESTIGATOR_450777] 
 
[ADDRESS_574823] Protocol V5.0 6 May 2022 lack of blinding.  We will also ask the person performing clinical assessments to provide his/her best guess regarding 
treatment allocation at the final study to ascertain whethe r we were successful in ma intaining a blinded assessor. 
6.10. Assessment of Compliance 
 
Participants will be given a daily log to complete through th e course of the study to allow assessment of compliance in 
applying the traction hand orthosis or th e resting hand orthosis on a daily basis.  Participants will be reminded to 
complete this daily log on a weekly basis by [CONTACT_450835].  We will ask the participants turn in the daily log 
at their final in person [ADDRESS_574824] pa rticipants on a weekly basis via participants’ preferred 
method of contact: [CONTACT_6968], text or phone to  ask participants the following questions: 
1. Do you feel the orthosis is helpful? (0 – 100) 
2. Did you wear your hand orthosis this week?  Y/N 
3. (If the person did not wear the orthosis) – Why didn’t you wear your orthosis? 
4. How many times did you MISS wearing the orthosis this week?  
5. (If there were days that the participant didn’t wear  the orthosis) – Why didn’t you wear the orthosis 
every time? 
6. On average, how long have you been wearing the orthosis each night? (number of hours) 
7. Have you been completing your daily log? Y/N 
8. Have you had any problems with the orthosis? Y/N – if yes, fill out adverse event form.  
To maintain blinding of our Research Coordinator, we will no t make specific mention of what kind of orthosis was used 
for each participant.  These responses will be recorded in our main database.  At the end of each contact [CONTACT_2929], we will 
also use this as an opportunity to remi nd participants to wear their orthoses every morning and night to increase the 
likelihood of effectiveness of the orthoses.   
6.[ADDRESS_574825] sign off on their training and 
maintain documentation of training through the course of the study.  Details of the training are provided in the MOOP 
(Section 6.2). 
7.0 Study Intervention Discontinuation/ Pa rticipant Discontinuation / Withdrawal 
7.1 Participan t Withdrawal 
Participants may withdraw voluntarily from the study.  In ad dition, participants may discontinue the study intervention, 
but remain in the study for follow-up if he/she wishes.  A dedicated Case Report Form (CRF) administered on RedCap 
entitled “Withdrawal Form” will be completed by [CONTACT_450836]/withdrawal. 
 
Principal Investigator: [CONTACT_70798], Grace, Hsiao-Wei                                                                                             A Pi[INVESTIGATOR_450777] 
 
[ADDRESS_574826] Protocol V5.0 6 May 2022 7.2 Discontinuation of Study Intervention 
The PI [INVESTIGATOR_147140] a participant from the study for the following reasons: 
 
 Inability to fit the hand orthosis after a good  will effort by [CONTACT_450837]. 
 Pregnancy 
 If any clinical adverse event (AE) occurs such that cont inued participation in the study would not be in the best 
interest of the participant 
 If early termination of the study is deemed necessary 
 
At the time that the orthosis is created and customized for th e participant, our OT will provide instruction on how to don 
the orthosis and how to remove the orthosis .  She will also provide instruction to the participant that if the finger trap is 
uncomfortable and difficult to re move, there is always the option of cutting the finger trap off the finger with a pair of 
scissors.  Our OT will observe the participant donning and removi ng the orthosis in the clinical setting to verify that the 
participant has good understanding of how to perform these ac tivities.  She will also review with the participant how to 
cut the finger trap off in the setting that the participant is  unable to remove the finger trap.  She will also provide the 
participants with a handout describing these activities that part icipants can take with them.  If the participants still have 
difficulty donning and/or removing the orthoses, the participants  will be instructed to contac t our OT to schedule an as 
needed appointment to review how to perform these activities.    We will do our best to minimize any discomfort related to thes e orthoses as our OT will make every effort to address any 
discomfort the participants may complain of at the time th at the orthoses are created by [CONTACT_450838].  Also, we will schedule all part icipants to return for a [ADDRESS_574827] related to  the orthoses.  If these issues cannot 
be satisfactorily resolved, then the participants will be  given an option to terminate use of the orthosis.   
 Discontinuation from the study intervention does not me an discontinuation from the study, and remaining study 
procedures will be completed as indicated by [CONTACT_4690].   If a clinically significant finding is identified (including, 
but not limited to changes from baseline) after enrollment, th e investigator or qualified designee will determine if any 
change in participant management is n eeded. Any new clinically relevant finding will be reported as an adverse event 
(AE). 
 
A dedicated Case Report Form (CRF) administered on RedCap  entitled “Early Termination Form” will be completed by 
[CONTACT_450839]. 
Subjects who sign the informed consent fo rm and are randomized but do not receiv e the study intervention will still be 
included in the baseline demographics description.  Missing outcomes among participants who missed pain and function 
questions or lost to follow up will be addressed by [CONTACT_450840]. 
Under the assumption of missing at random, we will include factors which may be related to missing of outcome in the 
imputation, such baseline demographic characteristics, dise ase severity, etc. We can us e this method of imputation 
because all outcomes are continuous and they can be assumed to follow multivariate normality distribution. To use this 
method of multiple imputations, there is an assumption of missing at random.  Th ough this assumption is not testable, 
multiple imputation method are viewed as less biased than a completers’ analysis, last observation carried forward, and 
single imputation method.
55   Subjects who sign the informed consent form, and are randomized and receive the study 
intervention, and subsequently withdraw, or are withdrawn or discontinued from the study, will not be replaced.  
 
Principal Investigator: [CONTACT_70798], Grace, Hsiao-Wei                                                                                             A Pi[INVESTIGATOR_450777] 
 
[ADDRESS_574828] be taken if a participant fails  to return to the clinic for a required study visit: 
 The site will attempt to contact [CONTACT_62541] 14 days and counsel the 
participant on the importance of maintaining the assigne d visit schedule and ascertain if the participant wishes 
to and/or should continue in the study. 
 Before a participant is deemed lost to follow-up, the in vestigator or designee will make every effort to regain 
contact [CONTACT_6635] (where possible, 3 teleph one calls and, if necessary, a certified letter to the 
participant’s last known mailing address). These contact [CONTACT_13140]’s 
study file.  
 Should the participant continue to be unreachable, he or  she will be considered to have withdrawn from the 
study with a primary reason of lost to follow-up.  
8.[ADDRESS_574829] of care treatment that includes a resting hand splint.  
 The primary symptom endpoint will be pain as assessed on a visual analog scale (VAS) in the more symptomatic 
hand that includes the most 
symptomatic DIP joint by [ADDRESS_574830] of care treatment for hand OA to establish efficacy of traction therapy.   
 This outcome measure has been recommended by [CONTACT_450841]: Design and conduct of clinical trials for hand osteoarthritis.
[ADDRESS_574831] of care treatment that includes a resting hand splint. 
 The primary structure endpoint will 
be change in sum of the Kellgren and 
Lawrence score
45 of all DIPs in the 
hand that was braced over 24 weeks.   The use of radiographic 
imaging as a means of 
measuring structural 
outcome has been recommended by [CONTACT_450842]: 
Design and conduct of 
clinical trials for hand osteoarthritis.
44 
Although there are 
 
Principal Investigator: [CONTACT_70798], Grace, Hsiao-Wei                                                                                             A Pi[INVESTIGATOR_450777] 
 
[ADDRESS_574832] of care treatment for hand 
OA to further support efficacy of 
traction therapy.  These outcomes will include: 
 The Functional Index for 
Hand Osteoarthritis (FIHOA)
42 
 The Disabilities of Arm 
Shoulder and Hand (DASH)49-
51 
 The Functional Dexterity 
Test43  
 Grip strength  
 Pi[INVESTIGATOR_32261] 
 Tenderness on joint 
palpation.  
 As this is a pi[INVESTIGATOR_799], 
we are making an 
attempt to include 
other measures that might also be of relevance and may 
perhaps be more 
useful in the follow up study to this pi[INVESTIGATOR_2268].  
The secondary structure objectives are to assess whether traction therapy plus standard of care treatment for nodal OA reduces structural progression compared 
with standard of care treatment 
that includes a resting hand splint.  The secondary structure endpoints 
will be  change in sum of the 
following scores all DIPs in the hand that was braced over 24 weeks: 
 joint space narrowing 
 osteophyte scores 
 Verbruggen-Veys scores Although a 24 week 
follow up time period might be too short to see a difference in the treatment arms, it is 
worth a look at the 
different radiographic features of OA to see if they are different between the two 
treatment arms. 
Tertiary/Exploratory    
 
Principal Investigator: [CONTACT_70798], Grace, Hsiao-Wei                                                                                             A Pi[INVESTIGATOR_450777] 
 
[ADDRESS_574833] Protocol V5.0 6 May 2022 OBJECTIVES ENDPOINTS JUSTIFICATION FOR 
ENDPOINTS 
The tertiary / exploratory structure 
objective is to assess whether 
traction therapy plus standard of 
care treatment for nodal OA 
modifies features of OA seen on 
MRI more compared with standard of care treatment that includes a 
resting hand splint. The exploratory endpoints include 
measurement in the most 
symptomatic DIP:  
 collateral ligament thickening 
 enthesial bone marrow 
edema 
 erosions  
 
Because this is a pi[INVESTIGATOR_450791], we are only evaluating these 
changes on 5 people in each 
treatment arm.    Prior observational 
studies indicated that 
there is pathology in 
these structures 
visualized on MRI.
15,16,36  
Perhaps these might change over a shorter 
period of time than 
radiographs.  If there is a signal with these 
measures then we 
might include MRI for all participants for the 
follow up clinical trial.  
The tertiary / exploratory clinical assessment objective is to evaluate 
whether traction therapy plus 
standard of care treatment for 
nodal OA modifies visual appearance of Heberden’s nodes 
using photographs compared with 
standard of care treatment that includes a resting hand splint. Visual inspection of the digital 
photographs for differences in 
erythema of the most symptomatic 
DIPs. This is a low risk 
outcome measure.  
Although it is not 
currently viewed as a 
standard outcome measure, if we can 
show this is a useful 
outcome measure this might serve as 
preliminary evidence to 
use this in our follow up study. 
Table 3. Study Objectives, Endpoints, an d the Justification of those Endpoints. 
  
8.2. Symptom Efficacy Assessments 
All of the following assessments will be made by [CONTACT_450843].  These will include: 
Outcomes: (Assessed at the baseline, week 4, week 12, and week 24 visits) 
 
Principal Investigator: [CONTACT_70798], Grace, Hsiao-Wei                                                                                             A Pi[INVESTIGATOR_450777] 
 
[ADDRESS_574834] Protocol V5.0 6 May 2022  the VAS pain scale, asking about pain in the hand th at includes the most symptomatic DIP over the last 
48 hours (primary outcome) 
 Australian Canadian Hand OA Index (AUSCAN) pain scale,1,2 (although we have requested copyright 
permission to use the scale, we have yet to receive permission to do so – we plan to administer the outcome, but if not given permission, we will not publish with this data). 
 the VAS pain scale, asking about pain in the most symptomatic DIP in  the last 48 hours, 
 the AUSCAN function subscale,
1,2  
 the Functional Index for Hand Osteoarthritis (FIHOA)42 
 the Disabilities of the Arm, Shoulder, and Hand (DASH)51,  
 the Michigan Hand Outcomes56, 
 the Functional Dexterity Test43,  
 grip and pi[INVESTIGATOR_32261], and  
 tenderness on joint palpation on all hand joints.44   
 photographs of the participant’s hands 
 We will also take a medication inventory (dichotomous assessments) 
i. Pain medications (e.g. acetaminophen, all non- steroidal anti-inflammatory medications, and 
opi[INVESTIGATOR_450803]). 
ii. Glucosamine and chondroitin 
iii. Marijuana use  
8.3. Additional co-variates of interest include:  
 age, (Assessed at baseline visit only)  
 sex, (Assessed at baseline visit only)  
 race / ethnicity, (Assessed at baseline visit only)  
 body mass index, (Assessed at baseline visit only)  
 co-morbidities,57 (Assessed at baseline visit only)  
 a family history of hand OA, (Assessed at baseline visit only)  
 occupations that they have performed in their life, (Assessed at baseline visit only)  
 
Principal Investigator: [CONTACT_70798], Grace, Hsiao-Wei                                                                                             A Pi[INVESTIGATOR_450777] 
 
[ADDRESS_574835] Protocol V5.0 6 May 2022  time spent on electronics (including smart phones, tablets, and computers) (Assessed at the baseline, week 
4, week 12, and week 24 visits)  
 International Physical Activity Questionnair e (iPAQ) questionnaire on physical activity,6 (Assessed at the 
baseline, week 4, week 12, and week 24 visits)  
 Center for Epi[INVESTIGATOR_6328] (CES-D).3 (Assessed at the baseline, week 4, week 12, and 
week 24 visits)  
These data will help to assess whether randomization was su ccessful and perhaps identify potential mediators to the 
effect of the traction orthosis.   
8.4. Structural Modification Assessments 
8.4.i. Posterior-Anterior Hand Radiographs (Obtained at the baseline and 24 week follow up visits) 
Standardized bilateral posterior-anteri or hand radiographs will be obtained on all participants using the same 
standardized operating procedure to minimize variability betw een studies.  These images w ill be scored for Kellgren and 
Lawrence scores45 (primary structure outcome), joint sp ace narrowing, and osteophyte scores,[ADDRESS_574836] an MRI performed of one DIP to be included 
in this group.   
8.4.iii. High Resolution MRI Im aging (Obtained at the week 2 and 24 week follow up visits) 
On 5 participants in each trea tment arm (for a total of 10 participants), we will obtain high resolution MRI imaging of the 
most symptomatic DIP joint.   
The sequences that will be obtained will include the following:  
 3-Plane Localizer  
 Coronal T1 
 Coronal Proton Density 
 Coronal T2 Fat Suppressed  
 Axial T1 
 Sagittal Merge 3D 
 Coronal T1 Fat Suppressed with Gadolinium 
 Axial T1 Fat Suppressed with Gadolinium 
 
 
Principal Investigator: [CONTACT_70798], Grace, Hsiao-Wei                                                                                             A Pi[INVESTIGATOR_450777] 
 
[ADDRESS_574837] radiographs 
of the hand with and without the traction orthosis applied to assess whether applying this treatment results in an increase in joint space width.   
8.6 Monitoring Body Memb ership and Affiliation 
This study is funded by [CONTACT_450844] (NIAMS).  They have 
appointed a single Safety Officer who is impartial to this study , to oversee the risks and benefits as well as the adverse 
events associated with this study. 
Safety Officer: [CONTACT_450874] of Medicine, Division of Rheumatology and Immunology, University of [LOCATION_004], Los Angeles  
Conflict of Interests for Safety Officer:  
The Safety Officer should have no direct involvement with the study investigators or intervention.  He will sign a Conflict 
of Interest Statement which includes current affiliations, if  any, with any steering commi ttees or advisory councils 
associated with the study, pharmaceutical and biotechnology companies (e.g. stockholder, consultant), and any other 
relationship that could be perceived as a conflict of interest  related to the study and/or associated with commercial or 
non-commercial interests pertinent to study objectives.    
8.7 Safety Reporting 
8.7.a Adverse Event Definitions 
Adverse Event  (AE) – Any unfavorable and unintended diagnosis, si gn (including laboratory finding), symptom or disease 
temporarily associated with the study intervention. 
 AEs may or may not be related to the intervention.   
 AEs include: 
o any new events not present during the pre-intervention period or  
o events that WERE present during the pre-intervention period which have INCREASED in severity. 
Unexpected Adverse Event  – Any adverse event that is not pre-defined as a potential adverse event.   
Serious Adverse Event  (SAE) – Any untoward medical occurrence that results in: 
 death or is life threatening 
 requires or prolongs hospi[INVESTIGATOR_450804]: Lo, Grace, Hsiao-Wei                                                                                             A Pi[INVESTIGATOR_450777] 
 
[ADDRESS_574838] Protocol V5.0 6 May 2022  causes persistent or signifi cant disability/incapacity 
 represents other significant hazards or potentially serious harm to research 
participants or others 
This also includes any unanticipated problem that is definitely related to the intervention.  Unanticipated Adverse Device Effects  (UADE) - Any serious adverse effect on health or safety or any life-threatening 
problem or death caused by, or associated with, a device, if th at effect, problem, or death the frequency, specificity, or 
severity of which has not previously been identified in the in vestigational plan or applicatio n, or any other unanticipated 
serious problem associated with a device that relates to the rights, safety, or welfare of participants (21 CFR 812.) 
 
8.7.b Adverse Event Reporting 
Our Research Coordinator will assess for adverse events systematic ally at each in clinic visi t.  If an adverse event is 
detected, he will contact [INVESTIGATOR_124]. Lo to comple te adverse event(s) form(s) at each of those visits where the details of such 
adverse events will be recorded in RedC ap.  Additionally, should any adverse events be reported to our Research 
Coordinator between in clinic visits, all those events  will also be recorded in RedCap by [INVESTIGATOR_124]. Lo.   
8.7.c Severity Assessment of Adverse Event.   
All AEs will be assessed by [CONTACT_412116] a protocol defined grading system.  The following guidelines will be 
used to describe severity .  
 
 Mild (Grade 1) – Events require minimal or no treatment and do not interfere with the participant’s daily 
activities.  
 Moderate (Grade 2) – Events result in a low level of inconvenie nce or concern with the therapeutic measures. 
Moderate events may cause some interference with functioning. 
 Severe (Grade 3) – Events interrupt a participant’s usual daily acti vity and may require systemic drug therapy or 
other treatment. Severe events are usually potentially life-threatening or incapacitating.  Of note, the term 
“severe” does not necessarily equate to “serious”. 
 Life-threatening consequences  (Grade 4 ); Urgent intervention indicated. 
 Death related to AE (Grade 5) . 
 
8.7.d Relatedness Assessment of Adverse Event.   
• Definitely Related – There is clear evidence to suggest a causal relationship, and other possible contributing 
factors can be ruled out. The clinical event, including an  abnormal laboratory test re sult, occurs in a plausible 
time relationship to study intervention administration and cannot be explained by [CONTACT_19009]. The response to withdrawal of the study intervention (de-challenge) should be clinically 
plausible. The event must be pharmacologically or phenomenologically definitive, with use of a satisfactory re-challenge procedure if necessary. 
• Probably Related – There is evidence to suggest a causal relationship, and the influence of other factors is 
unlikely. The clinical event, including an abnormal labora tory test result, occurs within a reasonable time after 
administration of the study intervention, is unlikely to be attributed to concurrent disease or other drugs or 
 
Principal Investigator: [CONTACT_70798], Grace, Hsiao-Wei                                                                                             A Pi[INVESTIGATOR_450777] 
 
[ADDRESS_574839] Protocol V5.0 6 May 2022 chemicals, and follows a clinically re asonable response on withdrawal (de-challenge). Re-challenge information 
is not required to fulfill this definition. 
• Potentially Related – There is some evidence to suggest a causal relationship (e.g., the event occurred within a 
reasonable time after administration of the trial medica tion). However, other factors may have contributed to 
the event (e.g., the participant’s clinical condition, other concomitant events). Although an AE may rate only as 
“possibly related” soon after discovery, it can be flagge d as requiring more information and later be upgraded to 
“probably related” or “definitely related”, as appropriate. 
• Unlikely to be related – A clinical event, including an abnormal  laboratory test result, whose temporal 
relationship to study intervention administration makes a causal relationship improbable (e.g., the event did not 
occur within a reasonable time after administration of the study intervention) and in which other drugs or chemicals or underlying disease provides plausible explanat ions (e.g., the participant’s clinical condition, other 
concomitant treatments). 
• Not Related – The AE is completely independent of study inte rvention administration, and/or evidence exists 
that the event is definitely related to another etiology . There must be an alternat ive, definitive etiology 
documented by [CONTACT_15370]. 
 
8.7.e Definition of Expected and Unexpected Adverse Events.   
Expected  adverse reactions are AEs that are known to occur for the study intervention being studied and should be 
collected in a standard, systematic format using a gradi ng scale based on functional assessment or magnitude of 
reaction. Based on preliminary data used to prepare our st udy where some volunteers wore the traction orthosis, we 
expect the following possible adverse events. 
 Increased hand discomfort or pain 
 Skin breakdown, erythema, and/or blistering 
 Neurologic complaints such as numbness or tingling 
 Vascular complaints such as poor circulation to the fingers 
 The PI, [CONTACT_450872], will be responsible for determining whether an adverse event (AE) is unexpected .  We anticipate 
that the expected AEs might occur commonly but the severity will mostly be mild and rarely if ever will be severe.    An 
AE will be considered unexpected  if it is not included in th e above list of expected events.  Additionally, if the nature, 
severity, or frequency of the event is greater than what we h ave outlined, this will also be considered to be unexpected.  
 
8.7.f Determination of whether or not an Adverse Event is Serious.   
In the course of completing the adverse event forms, it will be determined whether or not it is a serious adverse event 
(see the definition in 8.7.a).   
8.7.g Time period and frequency for event assessment and follow up. 
The occurrence of an adverse event (AE) or serious adverse event (SAE) may come to the attention of study personnel 
during study visits and interviews of a study participant pres enting for medical care, or upon review by a study monitor. 
 
All AEs including local and systemic reactions not meeting the criteria for SAEs will be captured on the appropriate case 
report form (CRF) in RedCap. Information to be collected includes event descriptio n, time of onset, [CONTACT_435018]’s assessment 
of severity, relationship to traction versus standard orthos is, and time of resolution/stabilization of the event. All AEs 
occurring while on study must be documented appropriatel y regardless of relationship. All AEs will be followed to 
adequate resolution.  For an expected AE, follow up for 30 days after the onset of the AE will be considered as an 
adequate resolution. 
 
 
Principal Investigator: [CONTACT_70798], Grace, Hsiao-Wei                                                                                             A Pi[INVESTIGATOR_450777] 
 
[ADDRESS_574840] udy participant’s condition deteriorates at any time during the study, it will be 
recorded as an AE.  
 Changes in the severity of an AE will be  documented to allow an assessment of the duration of the event at each level of 
severity to be performed. AEs characterized as intermit tent require documentation of onset and duration of each 
epi[INVESTIGATOR_1865]. 
 
Our Research Coordinator, Michael Strayhorn, will record all reportable events with start dates occurring any time after 
informed consent is obtained until 7 (for non-serious AEs) or 30 days (for SAEs) after the last day of study participation.  
At each study visit (including in clinic visits and weekly  telephone calls), the investigator will inquire about the 
occurrence of AE/SAEs since th e last visit.  Events will be followed fo r outcome information until resolution or 
stabilization. 
8.7.h Timing of reporting of AEs and SAEs to monitoring entities 
Reporting of Nonserious Adverse Events   
Cascade of communication of non-serious adverse events  will be the following: 
1. The Research Coordinator will inform Dr . Grace Lo, the PI, of non-serious adve rse events as soon as they occur. 
2. [CONTACT_435018] will notify the NIAMS and Safety Officer of these events as part of the routine safety reports submitted 
biannually.  
3. [CONTACT_435018] will report on these events to the Baylor College  of Medicine IRB during our annual renewal, according to 
local IRB requirement.  
Cascade of communication of serious adverse events  will be the following: 
1. The Research Coordinator will inform Dr . Grace Lo, the PI, of serious adverse events as soon as they occur.  
2. [CONTACT_435018] will notify the NIAMS and Safety Officer within [ADDRESS_574841]. Lo will also report the Serious Adverse Events to th e MEDVAMC Research Office, the Privacy Officer, and the 
Facility Research Compliance Officer within 5 business days  of becoming aware of the event, according to VA 
Research and Development requirement.  
5. Specific triggers for an ad hoc review or initiation of  the process of an ad hoc review will occur if there are 
unforeseen deaths or the threshold for SAE (of more than 10) has been met. 
Additionally, all serious adverse events  will need to be assessed to ascertain: 
1. whether the adverse events are associated with one of the treatment allocation groups which may result in 
early study termination (performed by [INVESTIGATOR_124]. Richardson), and / or 
2. if changes to the protocol are required and / or  
 
Principal Investigator: [CONTACT_70798], Grace, Hsiao-Wei                                                                                             A Pi[INVESTIGATOR_450777] 
 
[ADDRESS_574842] Protocol V5.0 6 May 2022 3. if changes to the informed consent documents are required.   
 
The on-line FDA MedWatch reporting system  (Form FDA 3500 Voluntary Reporting) will be used to  record adverse 
events for distribution.  
- Serious adverse events will be reported using this schedule: 
o deaths: immediately, upon knowledge 
o all others: within [ADDRESS_574843]. Lo will review all adverse events on a weekly basis until their conclusion  OR consideration as chronic .  During each 
review, she will re-review whether there needs to be modification of the study intervention.   
 
8.8 Unanticipated Problem Reporting 
Unanticipated Problem  – defined by [CONTACT_450845], experience or outcome that meets ALL the following 
requirements: 
1. Unexpected  (in terms of nature, severity, or frequency) given (a) the research procedures that are described in 
the IRB-approved research protocol  and informed consent document; and (b) the characteristics of the 
population being studied. 
2. Related or possibly related to  participation in the research .  Possibly related means there’s a reasonable 
possibility that the incident, experience, or outcome may have been caus ed by [CONTACT_32015]. 
3. Suggests that the research places participants or others at a greater risk of harm  (including physical, 
psychological, economic, or social harm) th an was previously known or recognized.  
 
 
Principal Investigator: [CONTACT_70798], Grace, Hsiao-Wei                                                                                             A Pi[INVESTIGATOR_450777] 
 
[ADDRESS_574844] Protocol V5.0 6 May 2022  
Figure 8. Flowchart indicating the determination of whether an adverse event is an unanticipated problem.  
To be clear, only a SMALL number of serious adverse events w ill fit into this category.  Addi tionally, there are situations 
not considered adverse events that can be considered an unanticipated problem.    
The following Venn diagram summarizes the general relationship between adve rse events and unanticipated 
problems:  

 
Principal Investigator: [CONTACT_70798], Grace, Hsiao-Wei                                                                                             A Pi[INVESTIGATOR_450777] 
 
[ADDRESS_574845] Protocol V5.0 6 May 2022  
Figure 9. Venn diagram indicati ng the overlap of adverse event s with unanticipated problems. 
The diagram (figure 9) illustrates three key points: 
 The vast majority of adverse events occurring in hum an subjects are not unanticipated problems (area A). 
 A small proportion of adverse events are unanticipated problems (area B). 
 Unanticipated problems include other incidents, experience s, and outcomes that are not adverse events (area C). 
[Aside:  
An example of an area C unanticipated problem would be: 
An investigator conducting behavioral research collects indivi dually identifiable sensitive information about illicit drug use and 
other illegal behaviors by [CONTACT_29759].  The data are stored on a laptop computer without encryption, and the 
laptop computer is stolen from the investigator’s car on the wa y home from work.  This is an unanticipated problem that must 
be reported because the incident was (a) unexpected (i.e., th e investigators did not anticipate the theft); (b) related to 
participation in the research; and (c) placed the subjects at a gr eater risk of psychological and social harm from the breach i n 
confidentiality of the study data than was previously known or recognized.  
 
For additional examples: https://www.hhs.gov/ohrp/regulations-and-po licy/guidance/reviewing-unanticipated-
problems/index.html#AB  ] 
 
Upon notification of an Unanticipated Problem , the Research Coordinator  will notify all appropriate parties as outlined 
below: 
1. The Research Coordinator will immediately  notify the PI, [CONTACT_450872]  via emergency contact [CONTACT_3031]. 
2. [CONTACT_435018] will notify the NIAMS and Safety Offi cer (through the NIAMS Executive Secretary) within [ADDRESS_574846]. Lo  and once 
modified and approved, will be sent to the IRB . 

 
Principal Investigator: [CONTACT_70798], Grace, Hsiao-Wei                                                                                             A Pi[INVESTIGATOR_450777] 
 
[ADDRESS_574847]. Lo will determine the study’s status and notify the Study Team. 
6. [CONTACT_435018] will also report the Unanticipated Problem to th e MEDVAMC Research Office, the Privacy Officer, and the 
Facility Research Compliance Officer within [ADDRESS_574848] 
deviations for VAS scores for comfort level while wearing th e orthosis ease/difficulty of donning the orthoses, how well 
they like the orthoses, and overall hand pain using visual analog scales (VAS), providi ng scores from [ADDRESS_574849] 
symptomatic joint and of all DIPs.   For functional ou tcomes, we will evaluate the AUSCAN function subscale,1,2 the 
Functional Index for Hand Osteoarthritis (FIHOA),42 the Disabilities of the Arm, Shoulder, and Hand (DASH),[ADDRESS_574850],43 grip and pi[INVESTIGATOR_32261].44  
We will complete descriptive analyses of baseline characteri stics of the treated and control groups to allow assessment 
of generalizability and success of randomization. We will use either Student t-tests or rank-based nonparametric tests 
where appropriate. Our primary analytic approach will be to  use intention- to-treat (ITT)  analyses to compare mean 
change of each symptom and function outcome during follow- up between traction therapy and the control groups with 
linear regression model for longitudinal repeated measures  data.  Missing outcomes among participants who missed 
pain and function questions or lost to follow up will be a ddressed by [CONTACT_450846]. Under the assumption of missing at random, we  will include factors which may be related to missing of 
outcome in the imputation, such baseline demographic characte ristics, disease severity, etc. We can use this method of 
imputation because all outcomes are continuous and they ca n be assumed to follow multivariate normality distribution. 
To use this method of multiple imputations, there is an assu mption of missing at random.  Though this assumption is not 
testable, multiple imputation method ar e viewed as less biased than a complete rs’ analysis, last observation carried 
forward, and single imputation method.[ADDRESS_574851] in our inclusion of 
outcome measures we will evaluate.  The primary structural  outcome measure will be change in sum of the Kellgren and 
Lawrence score of all DIPs in the hand that was braced.44   We will also evaluate change in joint space narrowing, and 
osteophyte scores46 and the  Verbruggen-Veys 47 from baseline to 6 month follow up comparing the traction versus the 
control groups.  For those randomized to traction, we will also  compare the hand that received  traction to the hand that 
did not.  To address potential missing data, we will use a multiple imputation method, assuming the data are missing at 
 
Principal Investigator: [CONTACT_70798], Grace, Hsiao-Wei                                                                                             A Pi[INVESTIGATOR_450783] 
 
[ADDRESS_574852] Protocol V5.0 6 May 2022 random.  We will perform an ANOVA to compare mean chan ge in the sum of radiographic scores over the 6 month 
follow up period between the traction therapy and the 
control groups.  If there are unbalanced baseline 
covariates between the treatment groups, we will use an ANCOVA approach to include them as covariates in the analysis.   
Power calculation:  Assuming the SD of change in the 
summary score is 3, we can expect at least 80% power to 
detect a difference of 1.7 in the change of the summary score between the two arms wi th 100 participants (50 in 
each arm) for a two-sided type 1 error rate of 5%.  
On 5 participants in each treatment arm (age and sex 
matched) for whom we will have high resolution MRI 
imaging at baseline and at [ADDRESS_574853] 
symptomatic DIP at baseline and then at 6 months to 
see if we can identify any  differences by [CONTACT_137459]. 
  
10.0 Supporting Documentation and Operational Considerations 
10.1 Protocol Deviations 
A protocol deviation is any noncompliance with the clinical  trial protocol, International Conference on Harmonization 
Good Clinical Practice (ICH GCP), or Manual of Procedures (MOOP) requirements. The noncompliance may be either on 
the part of the participant, the investigator, or the study site  staff. As a result of deviat ions, corrective actions are to be  
developed by [CONTACT_3483].   It is the responsibility of the site investigator to use cont inuous vigilance to identify an d report deviations within [ADDRESS_574854] (IRB) within 5 business days of becoming aware of the event only if there is a compliance 
concern. The site investigator is respon sible for knowing and adhering to the reviewing IRB requirements. Further details 
about the handling of protocol deviations will be included in the MOOP.  
An example of a protocol deviation will include if the participant attends the in-person clinic visit outside of the visit 
window or a missed in person clinic visit.   
10.2 Study Discontinuation and Closure 
This study may be temporarily suspended or prematurely terminated if there is sufficient reasonable cause.  Written 
notification, documenting the reason for study suspension or termination, will be provided by [CONTACT_226737].  The PI [INVESTIGATOR_112578], the BCM IRB, the NIAMS and KAI of the Figure 10. Power curve for change in the DIP summary 
score change in finger traction v. control groups.   

 
Principal Investigator: [CONTACT_70798], Grace, Hsiao-Wei                                                                                             A Pi[INVESTIGATOR_450777] 
 
[ADDRESS_574855] Protocol V5.0 6 May 2022 suspension or termination and provide the reason(s) for such ac tion.  Study participants will be contact[INVESTIGATOR_530], as applicable, 
and be informed of changes to study visit schedule.   
Circumstances that may warrant termination or suspension include, but are not limited to: 
 Determination of unexpected, significant, or unacceptable risk to participants 
 Demonstration of efficacy that would warrant stoppi[INVESTIGATOR_007]    
 Insufficient compliance to protocol requirements 
 Data that are not sufficiently complete and/or evaluable 
 Determination that the primary endpoint has been met 
 Determination of futility 
 
Study may resume once concerns about safety, protocol compliance, and data quality are addressed, and satisfy the 
NIAMS, BCM IRB and/or Food and Drug Administration (FDA).  If the study is prematurely terminated, refer to Section 7.2, Study Intervention Discontinuation , for handling of enrolled 
study participants. 
10.3 Data Archiving / Quality Control / Quality Assurance.  All study data will be collected and managed using the 
REDCap electronic data capture tools, de signed to comply with HIPAA regulations.7,[ADDRESS_574856] udies from anywhere in the world with 
secure web authentication, data logging, and Secure Sockets Layer (SSL) encryption.7  It provides: 1) an intuitive interface 
for validated data entry  2) audit trails  for tracking data manipulation and export procedures 3) automated export 
procedures  for seamless data downloads to common statistical pack ages, an essential feature for data back-up and 4) 
user-friendly procedures for importing data from external sources.[ADDRESS_574857] Itanium System running under the UNIX operating system. This server is used for ma naging and analyzing the large datasets. The Itanium server 
has four 1.5-gigahertz (GHz) Itanium central processing units (C PUs) that have instruction set architecture of 64 bit Intel 
microprocessors (IA64), 28.0 gigaby[INVESTIGATOR_040] (GB) of random access memory (RAM), and approximately 8 teraby[CONTACT_355465] (TB) of disk 
storage. In addition to the Hewlett-Packard Itanium, si x Dell servers run the Windows operating system, used for 
network applications, Structured Query Language (SQL) databa se, file sharing, and print sharing with a total storage 
capacity of 4TB. 
 
10.4 Publication and Data Sharing Policy.    
National Institutes of Health (NIH) Public Access Policy, wh ich ensures that the public ha s access to the published results 
of NIH funded research. It requires scientists to submit final peer-reviewed journal manuscripts that arise from NIH 
funds to the digital archive PubMed Central  upon acceptance for publication. 
 
This study will comply with the NIH Da ta Sharing Policy and Policy on the Dissemi nation of NIH-Funded Clinical Trial 
Information and the Clinical Trials Registration and Result s Information Submission rule. As such, this trial will be 
registered at ClinicalTrials.gov, and result s information from this trial will be subm itted to ClinicalTrials.gov. In addition,  
 
Principal Investigator: [CONTACT_70798], Grace, Hsiao-Wei                                                                                             A Pi[INVESTIGATOR_450777] 
 
[ADDRESS_574858]. Grace Lo.  
10.5 Manual of Operations  
We will develop additional sections for the MOOP that describe  in detail the procedures involved in this proposal. This 
will include a staff certification prot ocol and quality control activities. 
10.6 Study Timeline 
Activities Year 1 Year 2 Year 3 
Write and finalize clinical protocol for the study                         
Registration of clinical trial in ClinicalTrials.gov             
Creating Data Collection Platform                         
Local IRB Application/Approval                         
Completion of Regulatory Approvals             
Beta Testing of On-line Data Collection                         
Training Clinical Staff                         
Stocking Finger Traps in Preparation for the Trial                         
Recruitment of Participants/ 
Baseline Assessments/Randomization/ 
Fabrication of Orthoses /  
Non-Pharm Standard of Care                         
    Enrollment of first participant                        
First 25%                         
Second 25%                         
Third 25%                         
Fourth 25%                         
Follow up of Participants                         
First 25%                         
Second 25%                         
Third 25%                         
Fourth 25%                         
Baseline Radiographs                         
First 25%                         
Second 25%                         
Third 25%                         
Fourth 25%                         
[ADDRESS_574859] 25%                         
Second 25%                         
 
Principal Investigator: [CONTACT_70798], Grace, Hsiao-Wei                                                                                             A Pi[INVESTIGATOR_450777] 
 
[ADDRESS_574860] 25%                         
Fourth 25%                         
Proof of Concept X-Rays (10 participants)                         
Baseline MRIs (10 participants)                         
6 Month MRIs (10 participants)                         
Prepare Xrays and MRIs for Readings                         
Xray and MRI readings                          
Completion of Data Collection             
Statistical Analyses                         
Completion of Primary and Secondary Endpoint 
Analyses             
C o m p l e t i o n  o f  F i n a l  S t u d y  R e p o r t              
R01 Application                         
Manuscript Writing             
Reporting of Results to ClinicalTrials.gov                         
 
Table 4. Estimated Timeline of Study Events 
  
 
Principal Investigator: [CONTACT_70798], Grace, Hsiao-Wei                                                                                             A Pi[INVESTIGATOR_450777] 
 
[ADDRESS_574861] Protocol V5.0 6 May 2022 10.7 Participant Safety 
10.7.a Risks to Human Subjects 
Human Subjects Involvement, Characteristics, and Design  
In our study, we propose a pi[INVESTIGATOR_450805] 40 participants recruited from the Michael E. 
DeBakey VA Medical Center (MEDVAMC) with at least 3 joints  affected by [CONTACT_450817] (DIP) nodal hand OA, 
with at least one joint with frequent pain.  The hand with the DIPs with the greatest severity level of pain will be eligible 
for randomization into (1) standard of care or (2) traction plus standard of care.  If results from this study support 
feasibility, proof of concept that finger traps provide tracti on, symptomatic/functional improvement with traction, we 
will use findings from this study to inform a larger R01 study  that can be adequately powe red to address efficacy and 
utility of this treatment in the general clinical setting.   
 We will be recruiting people who are patients at the MEDVAMC in the outpatient setting through fliers posted in clinics 
as well as throughout the facility where outpatients spend ti me, including the cafeteria, the canteen, coffee stands, the 
phlebotomy lab and the information desk.  Additionally, we VA pa tients who are identified as likely to be eligible for our 
study through clinic patient lists who do not opt out of cont act by [CONTACT_450847].  At enrollment,  participants cannot be hospi[INVESTIGATOR_057].  However,  if participants become hospi[INVESTIGATOR_450806]-up, they will be allo wed to continue in the study.  We will make every effort to determine whether 
participation in the study is related to  the participant’s hospi[INVESTIGATOR_059].  
 
As this is a pi[INVESTIGATOR_799], we have chosen a relatively small nu mber of participants to enroll into this study.  Information 
from this study will help to better info rm an appropriate size for a study that could definitively assess efficacy of our 
proposed study treatment.  To allow for comparability of our two groups, and to a llow for all participants to receive the 
standard of care, we are recruiting people who are establis hed at the MEDVAMC.  Thus, participants will be at least [ADDRESS_574862] that prisoners or institut ionalized individuals will learn about this study and therefore 
will not be recruited into the study.  Therefore, no vulnerable  populations will be included in this study so none of these 
groups will be placed at increase d risk relative to other participants included in our study.   
 
Once a participant is deemed eligible for participation into the study and is consented for the study, he/she will have all 
his/her baseline assessments administered  by [CONTACT_254205].  After this is completed, the research 
coordinator will email [CONTACT_241940], our statistician, wh o will generate a randomization assignment (designated as 
group A v. group B) stratified by [CONTACT_547].  This allocation assignment will only be transmitted to our OT by [CONTACT_450848]-pharmacologic interventions for hand OA that 
are considered standard of care.  Prior to the beginning of the study, the OT will use a coin flip to decide which group (A 
v. B) will be the treatment v. control group.  The OT will be  the only person in the inve stigative team to know this 
 
Principal Investigator: [CONTACT_70798], Grace, Hsiao-Wei                                                                                             A Pi[INVESTIGATOR_450777] 
 
[ADDRESS_574863] Protocol V5.0 6 May 2022 designation until the study data set is closed and all analyses  are finalized.   At that po int, the OT will customize the 
appropriate orthosis for the participant to take with him/her.   
 
We will ask the participants wear the traction and the rest ing orthoses every night for 30- [ADDRESS_574864] ralian Canadian Hand OA Index (AUSCAN) pain scale, the 
VAS pain scale, the AUSCAN function subscale, the Functional Index for Hand Osteoarthritis (FIHOA), and the Disabilities 
of the Arm, Shoulder, and Hand (DASH). We will also ask partic ipants to report occupations that they have performed in 
their life.  We will also ascertain data on time spent on el ectronics (including smart phones, tablets, and computers).  We 
will also administer a validated physical activity questio nnaire and a questionnaire on occupational activities. 
Additionally, we will perform a medication inventory including  pain medications (e.g. acetaminophen, all non-steroidal 
anti-inflammatory medications, and opi[INVESTIGATOR_37007]). We will also collect data on po tentially important covariates 
such as age, sex, and body mass index and a family history of hand OA.  We will also electronically record results from 
the physical exam including the Functional Dexterity Test, grip and pi[INVESTIGATOR_32261], and tenderness on joint palpation. Additionally, we will obtain radiog raphs and MRIs of the hands.   
 
All study data will be collected and mana ged using the REDCap electronic data ca pture tools, designed to comply with 
HIPAA regulations.
7,8  This is a VA approved electronic data capture so ftware.  It is designed to  support data capture for 
research studies from anywhere in the world with secure web authentication, data logging, and Secure Sockets Layer 
(SSL) encryption.7  It provides: 1) an intuitive interface for validated data entry  2) audit trails  for tracking data 
manipulation and export procedures 3) automated export procedures  for seamless data downloads to common 
statistical packages, an essential feature for data back-up and 4) user-friendly procedures for importing data from 
external sources.[ADDRESS_574865] Itanium System running under the UNIX operating system. This server is used for 
managing and analyzing the large datasets. The Itanium server  has four 1.5-gigahertz (GHz) Itanium central processing 
units (CPUs) that have instru ction set architecture of 64 bit Intel microp rocessors (IA64), 28.0 gigaby[INVESTIGATOR_040] (GB) of random 
access memory (RAM), and approximately 8 teraby[CONTACT_355465] (TB) of di sk storage. In addition to the Hewlett-Packard Itanium, 
six Dell servers run the Windows operating system, used fo r network applications, Structured Query Language (SQL) 
database, file sharing, and print sharing with a total storage capacity of 4TB. 
 
All participants will be asked to  turn in log books that are labeled with their study ID to our OT.  In these log books, we 
will ask the participants to keep a daily log of when they apply and remove the orthoses, comfort level of the orthoses, 
 
Principal Investigator: [CONTACT_70798], Grace, Hsiao-Wei                                                                                             A Pi[INVESTIGATOR_450777] 
 
[ADDRESS_574866] Protocol V5.0 6 May 2022 ease/difficulty of donning the orthoses, how well they like th e orthoses, and overall hand pain using VAS scales.  These 
data will be kept in a locked cabinet and the data will be  transferred onto Red Cap to be managed in a similar manner 
that all the other clinic acquired data is managed.   
 All participants will have hand radiographs  obtained at the baseline and 6 mont h follow up visits at the MEDVAMC. 10 
participants, 5 (2 men, 3 women) in each treatment group, age matched within [ADDRESS_574867] 
symptomatic DIP joint at week 2 and 24 follow up visits, pe rformed at Baylor/St. Luke’s Medical Center Radiology 
Department.  At the 2-week visit, the same [ADDRESS_574868] radiographs obtained with and without the 
orthoses donned.  Radiographs when initially obtained will be stored on the MEDVAMC Pi[INVESTIGATOR_115306] (PACS) prior to transfer to one of our secure, password protected research server at the 
MEDVAMC. The MEDVAMC’s PACS system supp orts the clinical operations of the Hospi[INVESTIGATOR_307]. Access to this platform is 
strictly limited to essential clinical and approved research  staff through passwords and permission levels. MRIs obtained 
at Baylor/St. Luke’s Medical Center will be burned onto a CD/DVD which will then be imme diately uploaded and stored 
on our MEDVAMC research server secured through passwords , permission-levels and data encryption. Other digital 
data, including photographs of the hands that is collected th rough our electronic data colle ction system will be similarly 
stored on our the MEDVAMC rese arch server labeled with a study ID but othe rwise be de-identified and either stored on 
a secure server or in a lock ed cabinet.  Copi[INVESTIGATOR_112468]-identified ra diographs and MRIs will be burned onto DVDs/CDs 
and shipped with confirmed receipt to Drs. Haugen and Grai nger respectively so they can provide readings of those 
images for this study.       Potential Risks 
The risks to the participants for this study are small. For all participants of this study, the time involved in the in-person 
visits will be a lost resource for the participants.  Participants  will also be asked to have both hands imaged by 
[CONTACT_450849] [ADDRESS_574869]: 
 Increased hand discomfort or pain 
 Skin breakdown, erythema, and/or blistering 
 Neurologic complaints such as numbness or tingling 
 Vascular complaints such as poor circulation to the fingers 
 At the time that the orthosis is created and customized for th e participant, our OT will provide instruction on how to don 
the orthosis and how to remove the orthosis .  She will also provide instruction to the participant that if the finger trap is 
uncomfortable and difficult to re move, there is always the option of cutting the finger trap off the finger with a pair of 
scissors.  Our OT will observe the participant donning and removi ng the orthosis in the clinical setting to verify that the 
participant has good understanding of how to perform these ac tivities.  She will also review with the participant how to 
cut the finger trap off in the setting that the participant is  unable to remove the finger trap.  She will also provide the 
participants with a handout describing these activities that part icipants can take with them.  If the participants still have 
difficulty donning and/or removing the orthoses, the participants  will be instructed to contac t our OT to schedule an as 
needed appointment to review how to perform these activities.   
 
 
Principal Investigator: [CONTACT_70798], Grace, Hsiao-Wei                                                                                             A Pi[INVESTIGATOR_450777] 
 
[ADDRESS_574870] related to  the orthoses.  If these issues cannot 
be satisfactorily resolved, then the participants will be  given an option to terminate use of the orthosis.   
 Additionally, if the participants voice any complaint about the orthoses at any of the follow up visits, we will arrange an 
as needed appointment with our OT to address those conc erns. Again, if we are unable to adequately address a 
participant’s concerns or complaints then the participant of course, has the option to term inate use of the orthosis.   
 If participants experience skin break down in areas in contac t with the finger traps, they will be instructed to stop 
wearing the orthoses and to contact [CONTACT_450850]-assess fit of the orthosis at which 
time she can also make adjustments to improve fit if possible.   The participants will be inst ructed to resume wearing the 
orthoses after all skin break down is healed.    If participants experience neurologic and/or vascular compla ints (e.g. numbness/tingling or lack of blood supply) in the 
fingers that have finger traps applied, they will be instruct ed to stop wearing the orthos es and to contact [CONTACT_450851]-assess fit of the orthos is at which time she can also make adjustments to improve 
fit if possible.  The participants will be instructed to re sume wearing the orthoses after the participant can don the 
orthosis without the original complaint.    The alternative for people invited to be in this study is to decline participation in the study.  In this case, those people 
will still receive routine care by [CONTACT_450852].    
10.7.c Protections Against Risks 
10.7.c.i Informed Consent  
We will be recruiting people who are patients at the MEDVAM C through fliers posted in clinics as well as throughout the 
facility.  People who are interested in  knowing more about the study will contact [CONTACT_450853].  We will also screen patients from existing  clinic schedules and send potentially eligible participants a 
letter notifying them of our intent to contact [CONTACT_450854].  We will provide a phone number to call 
to opt out should they have no interest in  participating in our study.  For our study, the clinics that will be of interest wil l 
be the Women’s Health Clinics, Geriatrics  Clinics, and Primary Care Clinics.   
 
A telephone screening process will occur to assess for possibl e eligibility to enter the study.  During that screening 
process, our research coordinator will review a list of quest ions that will identify people  who are more likely to be 
eligible to enter our study.  No data will be collected on thes e people during this telephone call on RedCap.  We will keep 
a telephone screening log that will include the person’s na me, contact [CONTACT_3031], date of the telephone call, and 
scheduled date to come in for in-clinic scr eening.  This will be stored on a secure file on the M:drive in our study folder.  
This will not be maintained in RedCap. 
 At the in-person screening visit, our research coordinator will review the study consent fo rm with the participant and 
have the participant sign the form if th ey agree to participate in this study.  The consent form will include information 
allowing the participants to know that participation in the st udy is completely voluntary.  The participant will not be 
penalized if he/she decides not to participate in the study.  The participant can continue receiving usual care at the 
MEDVAMC just as he/she has in the past.  The participant will be told that this is a study of hand OA treatments but will 
not be told which treatment is experiment al to allow for double blinding in this study.  Participants will be allowed to 
 
Principal Investigator: [CONTACT_70798], Grace, Hsiao-Wei                                                                                             A Pi[INVESTIGATOR_450777] 
 
[ADDRESS_574871]: 
 Increased hand discomfort or pain 
 Skin breakdown, erythema, and/or blistering 
 Neurologic complaints such as numbness or tingling 
 Vascular complaints such as poor circulation to the fingers 
 Notably, finger traps are viewed by [CONTACT_415152] [ADDRESS_574872] 
difficulty donning and/or removing the orthoses, the participants  will be instructed to contac t our OT to schedule an as 
needed appointment to review how to perform these activities.   
 
We will do our best to minimize any discomfort related to thes e orthoses as our OT will make every effort to address any 
discomfort the participants many complain of at the time that the orthoses are created by [CONTACT_450838].  Also, we will schedule all participants to retu rn for a [ADDRESS_574873] related to  the orthoses.  If these issues cannot 
be satisfactorily resolved, then the participants will be  given an option to terminate use of the orthosis.   
 Additionally, if the participants voice any complaint about the orthoses at any of the follow up visits, we will arrange an 
as needed appointment with our OT to address those conc erns. Again, if we are unable to adequately address a 
participant’s concerns or complaints then the participant of course, has the option to term inate use of the orthosis.   
 If participants experience skin break down in areas in contac t with the finger traps, they will be instructed to stop 
wearing the orthoses and to contact [CONTACT_450850]-assess fit of the orthosis at which 
time she can also make adjustments to improve fit if possible.   The participants will be inst ructed to resume wearing the 
orthoses after all skin break down is healed.   
 If participants experience neurologic and/or vascular compla ints (e.g. numbness/tingling or lack of blood supply) in the 
fingers that have finger traps applied, they will be instruct ed to stop wearing the orthos es and to contact [CONTACT_450851]-assess fit of the orthos is at which time she can also make adjustments to improve 
 
Principal Investigator: [CONTACT_70798], Grace, Hsiao-Wei                                                                                             A Pi[INVESTIGATOR_450777] 
 
[ADDRESS_574874] Protocol V5.0 6 May 2022 fit if possible.  The participants will be instructed to re sume wearing the orthoses after the participant can don the 
orthosis without the original complaint.   
 
If there is detection of a high rate of unexpected adverse events grade 3 or higher, this may warrant termination or 
temporary suspension of the study (e.g., study closure based on PI [INVESTIGATOR_450807]/funder decision). For any study 
that is prematurely terminated or temporarily suspended,  [CONTACT_450872] will promptly inform the BCM/MEDVAMC IRB 
and NIAMS and provide the reason(s) for the termination or temporary suspension.  An in-depth investigation will be 
performed to determine whether there are study activities or treatment related effects that are contributing to this 
signal.  If the investigation does not support these possibilit ies, and this is agreed upon by [CONTACT_450855], the BCM/MEDVAMC 
IRB, and [CONTACT_450872], the study PI , then the study can resume.    
 We will make every effort to assure the confidentiality of human subj ects. Study identification codes that can link study 
data back to an individual’s name [CONTACT_450866] t will be created by [INVESTIGATOR_124]. Richardson.  We will store all clinic 
obtained data using REDCap electronic data capture tools, designed to comply with HIPAA regulations.
7,8  This is a VA 
approved electronic data capture software.  It is designed to  support data capture for research studies from anywhere in 
the world with secure web authentication, data lo gging, and Secure Sockets Layer (SSL) encryption.7  It provides: 1) an 
intuitive interface for validated data entry  2) audit trails  for tracking data manipulation and export procedures 3) 
automated export procedures  for seamless data downloads to common statisti cal packages, an essential feature for data 
back-up and 4) user-friendly procedures fo r importing data from external sources.[ADDRESS_574875] benefits related to this research are not enormous, the risks to subjects in this study are low; 
therefore risks to subjects are reasonable in relation to the anticipated benefits to the research participants and others.  
 
 
Principal Investigator: [CONTACT_70798], Grace, Hsiao-Wei                                                                                             A Pi[INVESTIGATOR_450777] 
 
[ADDRESS_574876] treatment for hand OA 
with both a symptom and structure benefit.  
10.10 Data and Safety Monitoring Plan 
Clinical and Data Monitoring Program 
10.10.a Part A: Clinical Monitoring Plan  
The purpose of this plan is to assure that our clinical tr ial is being conducted and document ed consistent with what is 
outlined in the Protocol, Standard Oper ating Procedures (SOPs), Good Clinical  Practice (GCP), and the applicable 
regulatory requirement(s).  As this is an exploratory double-blinded clinical trial that will be conducted at a single site of traction therapy using 
finger traps administered using a hand orthosis, a low risk in tervention, compared to standard of care for nodal distal 
interphalangeal hand osteoarthritis.  We are targeting enrollment of [ADDRESS_574877]. Grace Lo, the Principal 
Investigator [INVESTIGATOR_450808] / Michael E.  DeBakey VA Medical Center Institutional Review Board (IRB) 
will be responsible for the DSM Plan.   
Our plan is for continuous, close monitoring by [INVESTIGATOR_124]. Grace Lo, th e study PI, with prompt reporting of toxicity to the IRB, 
FDA and/or NIH.  We will monitor for to xicity through close monitoring of indi vidual patients and through statistical 
comparisons of treatment groups if needed.  Though we thin k the likelihood of these adverse events is low, potential 
side effects we will specifically report on the following possible adverse events:  
 Increased hand discomfort or pain 
 Skin breakdown, erythema, and/or blistering 
 Neurologic complaints such as numbness or tingling 
 Vascular complaints such as poor circulation to the fingers 
We aim to enroll [ADDRESS_574878] 3 joints affected by [CONTACT_450817] (DIP) nodal hand OA 
 - DIP nodal hand OA will be defined as Heberden’s nodes on physical exam.   - Sufficiently severe frequent pain of at least one DIP  - Frequent pain: pain on most days of the month for at least one month in the last year.    - Minimum VAS pain severity of 40 on a 0 – 100 scale 
Exclusion criteria  
- History or current inflammatory arthritides   (examples: gout, psoriatic arthritis, and rheumatoid arthritis) - Prior surgery on the DIP joints - Planned surgery for the DIP joints 
 
Principal Investigator: [CONTACT_70798], Grace, Hsiao-Wei                                                                                             A Pi[INVESTIGATOR_450777] 
 
[ADDRESS_574879] Protocol V5.0 6 May 2022 - Pregnancy 
 
This study will be monitored by a NIAMS-appointed safety officer (SO), [CONTACT_450875].  The SO will review reports 
electronically on a routine basis followi ng the introductory meeting. Ad hoc meetings may be scheduled as needed, but 
are not the typi[INVESTIGATOR_450809]-monitored studies.   
 Once enrollment begins, enrollment reports (template provided by  [CONTACT_450856]) will be sent monthly to KAI.  Safety reports will 
be sent twice a year to KAI and the Safety Officer.  These reports will include a detailed analysis of study progress, data 
and safety issues.  These reports will continue until the co mpletion of the last follow up visit of the last enrolled 
participant.  
Because this is a small study of short duration of a low risk treatment, we do not plan to have an interim analysis unless 
requested by [CONTACT_450857]/MEDVAMC IRB or NIAMS. 
During these reviews, our statistician (blinded to treatment allocation – though aware of group assignments as group A 
v. B), will systematically report:  
- CONSORT diagram and actual versus ex pected enrollment figures that illu strate recruitment and participation 
status.
1 
- Rate of screening potential participants (number of participants screened over how many months) 
- Rate of enrollment (number of partic ipants enrolled over how many months) 
- Rate of randomization (number of participants randomized over how many months) 
- Proportion of study completion (number of partic ipants who completed the 24 week follow up of the 
anticipated 40) 
- Proportion of study withdrawal (number of participants  who withdrew of the number successfully randomized) 
- Proportion of early termination of participants (num ber of participants who had early termination of the 
number successfully randomized) 
- Rate of treatment compliance  
- Data tables that summarize demographic and baseline clinical characteristics.  
- Data quality tables that capture missing visits and missing case report forms. 
- Safety assessments of aggregate tables of adverse events and serious adverse events.  
- Listings of adverse events, serious adverse even ts, deaths, unanticipated problems and protocol 
deviations/violations. 
- Any problems or issues with the conduct of the study not listed above. 
On a weekly basis , at our working meetings, [CONTACT_435018], the Research C oordinator, and our Statistician will review these 
same findings and evaluate whether there needs to be modification of the study intervention, modification of the 
protocol, modification of the consent form, or  early termination of the study.    If any of these concerns arise, [CONTACT_435018] will 
contact [CONTACT_450858].   
 
 
10.10.b Part B: Data Monitoring Plan  
Data collection is the responsibility of the clinical trial staff at the site under the supervision of the site investigator. T he 
investigator is responsible for ensuring the accuracy, comp leteness, legibility, and timeliness of the data reported. 
 
 
1 Schulz KF, Altman DG, Moher D, for the CONSORT Gr oup. CONSORT 2010 Statement: updated guidelines for 
reporting parallel group randomized trials. Ann Int Med 2010; 152 . 
 
Principal Investigator: [CONTACT_70798], Grace, Hsiao-Wei                                                                                             A Pi[INVESTIGATOR_450777] 
 
[ADDRESS_574880] on vhahouhsr10, and will be accessible through 
"\\r02.med.va.gov\Research\HOU\Production\Da ta\Housrd\Research\Lo _G_Hand_Study_H-[ZIP_CODE]". 
For all hard copi[INVESTIGATOR_156837], a binder system with a binder per participant will be created and maintained.  Our Research 
Coordinator will be responsible for creati ng and maintaining this system.  These binders will be maintained in double-
locked cabinets at MEDVAMC at [ADDRESS_574881] study data will be collected and managed using the REDCa p electronic data capture tools, designed to comply with 
HIPAA regulations.7,8  This is a VA approved electronic data capture so ftware.  It is designed to  support data capture for 
research studies from anywhere in the world with secure web authentication, data logging, and Secure Sockets Layer 
(SSL) encryption.7  It provides: 1) an intuitive interface for validated data entry  2) audit trails  for tracking data 
manipulation and export procedures 3) automated export procedures  for seamless data downloads to common 
statistical packages, an essential feature for data back-up and 4) user-friendly procedures for importing data from 
external sources.[ADDRESS_574882] participant enro lled is seen at his/her last in clinic visit.   
 This data will be stored on our M-drive folder  under the “Data Collection/Red_Cap” folder.   
 Each download will be stored usin g the following naming convention: RawDataHandRCT_<YYYYMMDD> .  
o In this naming convention , <YYYYMMDD> = year , month, date that the data was downloaded. 
Informed consent  is required by [CONTACT_450857]/MEDVAMC IRB to be obtained by [CONTACT_42574] a hard copy of the consent form 
and having the participant sign that hard copy.  Our Research  Coordinator will have this informed consent scanned and 
uploaded to the MEDVAMC electronic medical record system.  Additionally, he will scan and upload another copy of the 
consent form on   
 Our M-drive folder under the “Data  Collection/Consent” folder.   
 Each form will be stored using the following naming convention: Consent_<YYYYMMDD>_<studyID> .  
o In this naming convention: 
  <YYYYMMDD> = year, month, date that the consent was obtained 
 <studyID> = the participant’s study ID number. 
HIPAA form is required by [CONTACT_450857]/MEDVAMC IRB to be obtained by [CONTACT_42574] a hard copy of the HIPAA form and 
having the participant sign that hard copy.  Our Research Coordinator will have this HIPAA form scanned and uploaded 
to the MEDVAMC electronic medical record sy stem.  Additionally, he will scan and upload another copy of the form on    
 
Principal Investigator: [CONTACT_70798], Grace, Hsiao-Wei                                                                                             A Pi[INVESTIGATOR_450777] 
 
[ADDRESS_574883] Protocol V5.0 6 May 2022  Our M-drive folder under the “Data Collection/HIPAA” folder.   
 Each form will be stored using the following naming convention: HIPAA_<YYYYMMDD>_<studyID> .  
o In this naming convention: 
  <YYYYMMDD> = year, month, date that the HIPAA form was signed 
 <studyID> = the participant’s study ID number. 
 A hardcopy of the Daily Log  will be turned in by [CONTACT_450859] 24 month visit.  Our Research Coordinator will 
manually data enter all information from each daily log returned  electronically into an Excel spreadsheet file stored in 
the same M:drive file listed above.  We will make extra effort to verify that data recorded electronically will accurately 
reflect information derived from source documents. 
 This data will be stored on our M-drive folder under the “Data Collection/Daily_Log” folder.   
 Each week after the first daily log is  submitted and the forms are being data -entered, we will store a copy of the 
daily log stored using the follo wing naming convention: Daily_Log_ <YYYYMMDD>_<studyID> .  
o In this naming convention: 
  <YYYYMMDD> = year, month, date that the HIPAA form was signed 
 <studyID> = the participant’s study ID number. 
The original of the consent and HIPAA form and the daily log th at the participants will return at the end of the study will 
be stored in the study binders. 
Itemization of the data that will be co llected in RedCap in cludes the following: 
       Outcomes : 
 the VAS pain scale, asking about pain in the hand th at includes the most symptomatic DIP over the last 
48 hours (primary outcome) 
 Australian Canadian Hand OA Index (AUSCAN) pain scale,
1,2 (although we have requested copyright 
permission to use the scale, we have yet to receive permission to do so – we plan to administer the 
outcome, but if not given permission, we will not publish with this data). 
 the VAS pain scale, asking about pain in the most symptomatic DIP in  the last 48 hours, 
 the AUSCAN function subscale,1,2  
 the Functional Index for Hand Osteoarthritis (FIHOA)42 
 the Disabilities of the Arm, Shoulder, and Hand (DASH)51,  
 
Principal Investigator: [CONTACT_70798], Grace, Hsiao-Wei                                                                                             A Pi[INVESTIGATOR_450777] 
 
[ADDRESS_574884] Protocol V5.0 6 May 2022  the Michigan Hand Outcomes56, 
 the Functional Dexterity Test43,  
 grip and pi[INVESTIGATOR_32261], and  
 tenderness on joint palpation on all hand joints.44   
 photographs of the participant’s hands 
 We will also take a medication inventory (dichotomous assessments) 
iv. Pain medications (e.g. acetaminophen, all non- steroidal anti-inflammatory medications, and 
opi[INVESTIGATOR_450803]). 
v. Glucosamine and chondroitin 
vi. Marijuana use  
      Additional co-variates of interest include:  
 age, (Assessed at baseline visit only)  
 sex, (Assessed at baseline visit only)  
 race / ethnicity, (Assessed at baseline visit only)  
 body mass index, (Assessed at baseline visit only)  
 co-morbidities,57 (Assessed at baseline visit only)  
 a family history of hand OA, (Assessed at baseline visit only)  
 occupations that they have performed in their life, (Assessed at baseline visit only)  
 time spent on electronics (including smart phones, tablets, and computers) (Assessed at the baseline, week 
4, week 12, and week 24 visits)  
 International Physical Activity Questionnair e (iPAQ) questionnaire on physical activity,6 (Assessed at the 
baseline, week 4, week 12, and week 24 visits)  
 Center for Epi[INVESTIGATOR_6328] (CES-D).3 (Assessed at the baseline, week 4, week 12, and 
week 24 visits)  
These data will help to assess whether randomization was su ccessful and perhaps identify potential mediators to the 
effect of the traction orthosis.   
Clinical data (including adverse events (AEs), concomitant me dications, and expected advers e reactions data) and clinical 
laboratory data will be directly entered by [CONTACT_450860], a 21 CFR Part 11-compliant data 
 
Principal Investigator: [CONTACT_70798], Grace, Hsiao-Wei                                                                                             A Pi[INVESTIGATOR_450777] 
 
[ADDRESS_574885] protection and internal quality checks, such as 
automatic range checks, to identify data that a ppear inconsistent, incomplete, or inaccurate.  
 
For all participants who sign consent forms and HIPAA auth orization forms for an interventional study, to maintain 
compliance with VA Research and Development regulations, ou r Research Coordinator will write a “Protocol Entry Note” 
in the VA electronic medical record system, CPRS. For all ot her participant encounters related to the study, a “Research 
Note” will be recorded in the VA electronic medical system, CPRS. 
 
 
 
 
Procedures for Reporting Adverse Events ar e extensively outlined in section 8.7. 
 
Treatment Modification or Discontinuation 
People who are randomized into the traction therapy group may have: 
- discomfort related to wearing the orthosis 
- skin break down in areas in contact [CONTACT_450861]  
- neurologic and/or vascular complaints in the fingers that have finger traps applied  
 Notably, finger traps are viewed by [CONTACT_415152] [ADDRESS_574886] 
difficulty donning and/or removing the orthoses, the participants  will be instructed to contac t our OT to schedule an as 
needed appointment to review how to perform these activities.   
We will do our best to minimize any discomfort related to thes e orthoses as our OT will make every effort to address any 
discomfort the participants many complain of at the time that the orthoses are created by [CONTACT_450838].  Also, we will schedule all participants to retu rn for a [ADDRESS_574887] related to  the orthoses.  If these issues cannot 
be satisfactorily resolved, then the participants will be  given an option to terminate use of the orthosis.   
Additionally, if the participants voice any complaint about the orthoses at any of the follow up visits, we will arrange an 
as needed appointment with our OT to address those conc erns. Again, if we are unable to adequately address a 
participant’s concerns or complaints then the participant of course, has the option to term inate use of the orthosis.   
If participants experience skin break down in areas in contac t with the finger traps, they will be instructed to stop 
wearing the orthoses and to contact [CONTACT_450850]-assess fit of the orthosis at which 
time she can also make adjustments to improve fit if possible.   The participants will be inst ructed to resume wearing the 
orthoses after all skin break down is healed.   
 
Principal Investigator: [CONTACT_70798], Grace, Hsiao-Wei                                                                                             A Pi[INVESTIGATOR_450777] 
 
[ADDRESS_574888] Protocol V5.0 6 May 2022 If participants experience neurologic and/or vascular compla ints (e.g. numbness/tingling or lack of blood supply) in the 
fingers that have finger traps applied, they will be instruct ed to stop wearing the orthos es and to contact [CONTACT_450851]-assess fit of the orthos is at which time she can also make adjustments to improve 
fit if possible.  The participants will be instructed to re sume wearing the orthoses after the participant can don the 
orthosis without the original complaint.   
 Study Termination 
If there is detection of a high rate of unexpected adverse ev ents grade 3 or higher, which may or may not be associated 
with one treatment allocation group, this may warrant term ination or temporary suspension of the study (e.g., study 
closure based on PI [INVESTIGATOR_450807]/funder decision). For any study that is prematurely terminated or temporarily suspended, [CONTACT_450872] will promptly inform the BCM/ MEDVAMC IRB and NIAMS and provide the reason(s) for the 
termination or temporary suspension.  In depth investigatio n will be performed to determine whether there are study 
activities or treatment related effects that are contributing to  this signal.  If the investigation does not support these 
possibilities, and this is agreed upon by [CONTACT_450855], the BCM/ MEDVAMC IRB, and [CONTACT_450872], the study PI, then the study 
can resume.    
 
Describe methods and systems to ensure data confidentiality and subject privacy. 
All study personnel will be trained in best practices in hum an subjects studies prior to embarking on any study related 
activities and no study related activities will commence un til the study protocol is approved by [CONTACT_450862]/MEDVAMC’s IRB.  With the exception of a master list that links st udy ID to PHI, including first and last name, 
street address, email address, and phone number, all other st udy related materials will only be labeled with the study ID 
number to maximize the likelihood that data confidentiality will be maintained th rough the course of the study.  This 
master list will only be stored on a secured server within the MEDVAMC network , which is part of the VA nationwide 
network. Hence, our computers conform to VA security polic ies and standards. These policies and standards include but 
are not limited to strong passwords, locking screensavers, up-to-date anti-virus protection, and storage of sensitive 
patient information stored on VA servers on the VA netw ork. The servers are protected by [CONTACT_450816] .  All 
servers are backed up daily to ensure data protection. Week ly full backups are stored in  a vault at a secure remote 
location. The heart of the system is a Hewlett Packard Itan ium System running under the Unix operating system. This 
server is used for managing and analyzing the large datasets . The Itanium server has four 1.5-GHz Itanium CPUs (IA64), 
28.[ADDRESS_574889].  
 Describe process for locking the final trial datasets and the planned procedures on data access and sharing, as 
appropriate.  Once the final study participant has been s een for his/her [ADDRESS_574890]. Lo (PI) will make a  
best effort to reconcile logic errors and co mplete missing data if possible.  This should result in a complete and final trial 
dataset and [CONTACT_450876] (statistician) will then be asked to lock the dataset.  If data or resources from this 
project are requested by [CONTACT_450863], we will make every effort to 
share the data with those individuals using privacy respectf ul practices and following all th e guidelines expected when 
handling data from human subjects research.   
 
  
 
Principal Investigator: [CONTACT_70798], Grace, Hsiao-Wei                                                                                             A Pi[INVESTIGATOR_450777] 
 
[ADDRESS_574891] Protocol V5.0 6 May 2022 11.0 ClinicalTrials.gov Requirements 
ClinicalTrials.gov facilitates registration of trials in ac cordance with the Internationa l Committee of Medical Journal 
Editors (ICMJE) initiative requiring prior entry of clinical trials in a public registry as a condition for publication. 
Therefore, we will register this study with clinicaltrials.gov. Also, ClinicalTrials.gov allows the registration of trials that  (1) 
are approved by a human subject review board (or equivalen t) and (2) conform to the regulations of the appropriate 
national health authorities.  
  
 
Principal Investigator: [CONTACT_70798], Grace, Hsiao-Wei                                                                                             A Pi[INVESTIGATOR_450777] 
 
[ADDRESS_574892] Protocol V5.0 6 May 2022 12.0 References 
1. Nilsdotter AK, Lohmander LS, Klassbo M, Roos EM. Hi p disability and osteoarthr itis outcome score (HOOS)--
validity and responsiveness in total hip repl acement. BMC Musculoskelet Disord 2003;4:10. 
2. Fransen M, Anderson C, Douglas J, et al. Safety and efficacy of routine postoperative ibuprofen for pain and 
disability related to ectopic bone formation after hip repl acement surgery (HIPAID): randomised controlled trial. Bmj 
2006;333:519. 3. Radloff LS. The CES-D Scale: A self report depression scale for research in the general population. Applied 
Psychological Instruments 1977;1:385-401. 
4. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: Updated guidel ines for reporting parallel group 
randomised trials. J Pharmacol Pharmacother 2010;1:100-7. 5. Dowsey MM, Nikpour M, Dieppe P, Choong PF. Associ ations between pre-operative radiographic changes and 
outcomes after total knee joint replacement for os teoarthritis. Osteoarthritis Cartilage 2012;20:1095-102. 
6. Hagstromer M, Oja P, Sjostrom M. The Internationa l Physical Activity Questionnaire (IPAQ): a study of 
concurrent and construc t validity. Public Health Nutr 2006;9:755-62. 
7. . (Accessed 2016 June 29, at https://catalyst.harvard.edu/services/redcap/ .) 
8. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N,  Conde JG. Research electron ic data capture (REDCap)--a 
metadata-driven methodology and workflow process for provid ing translational research in formatics support. J Biomed 
Inform 2009;42:377-81. 9. Haugen IK, Englund M, Aliabadi P, et al. Prevalence, incidence and progression of hand osteoarthritis in the 
general population: the Framingham Osteoa rthritis Study. Ann Rheum Dis 2011;70:1581-6. 
10. Dahaghin S, Bierma-Zeinstra SM, Hazes JM, Koes BW. C linical burden of radiographic hand osteoarthritis: a 
systematic appraisal. Arthritis Rheum 2006;55:636-47. 
11. Slatkowsky-Christensen B, Mowinckel P, Loge JH, Kvien TK. Health-related quality of life in women with 
symptomatic hand osteoarthritis: a comparison with rheuma toid arthritis patients, healthy controls, and normative 
data. Arthritis Rheum 2007;57:1404-9. 12. Zhang W, Doherty M, Leeb BF, et al. EULAR evidence based recommendations for the management of hand 
osteoarthritis: report of a Task Force of the EULAR Sta nding Committee for International Clinical Studies Including 
Therapeutics (ESCISIT). Ann Rheum Dis 2007;66:377-88. 13. Hochberg MC, Altman RD, April KT, et al. American College of Rheumato logy 2012 recommendations for the use 
of nonpharmacologic and pharmacologic therapi[INVESTIGATOR_450810], hip, and knee. Arthritis Care Res 
(Hoboken) 2012;64:465-74. 
14. Kloppenburg M. Hand osteoarthritis-nonpharmacologic al and pharmacological treatments. Nat Rev Rheumatol 
2014;10:242-51. 15. Tan AL, Grainger AJ, Tanner SF, et al. High-resolut ion magnetic resonance imaging for the assessment of hand 
osteoarthritis. Arthritis Rheum 2005;52:2355-65. 16. Tan AL, Toumi H, Benjamin M, et al. Combined high-resolution magnetic resonance imaging and histological 
examination to explore the role of ligam ents and tendons in the phenotypic expre ssion of early hand osteoarthritis. Ann 
Rheum Dis 2006;65:1267-72. 17. Tan AL, Benjamin M, Toumi H, et al. The relationship be tween the extensor tendon enthesis and the nail in distal 
interphalangeal joint disease in psoriatic arthritis--a high-re solution MRI and histological study. Rheumatology (Oxford) 
2007;46:253-6. 
18. Tan AL, Grainger AJ, Tanner SF, Emery P, McGonagle D.  A high-resolution magnetic resonance imaging study of 
distal interphalangeal joint arthropathy in psoriatic arthritis and osteoarthritis: are they the same? Arthritis Rheum 2006;54:1328-33. 19. Sharma L, Dunlop D, Andriacchi TP , et al. The Adduction Moment and Knee Osteoarthritis (OA), a Longitudinal 
Study. Arthritis and Rheumatism 2003;48:Abstract #1131. 
 
Principal Investigator: [CONTACT_70798], Grace, Hsiao-Wei                                                                                             A Pi[INVESTIGATOR_450777] 
 
[ADDRESS_574893] Protocol V5.0 6 May 2022 20. Sharma L, Song J, Dunlop D, et al. Varus and valgus a lignment and incident and progressive knee osteoarthritis. 
Ann Rheum Dis 2010;69:1940-5. 
21. Sharma L, Song J, Felson DT, Cahue S, Shamiyeh E, Dunl op DD. The role of knee alignment in disease progression 
and functional decline in knee osteoarthritis. Jama 2001;286:188-95. 22. Felson DT, McLaughlin S, Goggins J, et al. Bone marrow edema and its relation to progression of knee osteoarthritis. Ann Intern Med 2003;139:330-6. 23. Hunter DJ, Zhang Y, Niu J, et al. Increase in bone ma rrow lesions associated with cartilage loss: A longitudinal 
magnetic resonance imaging study of knee os teoarthritis. Arthritis Rheum 2006;54:1529-35. 
24. Hunter DJ, Zhang YQ, Niu JB, et al . The association of meniscal pathol ogic changes with cartilage loss in 
symptomatic knee osteoarthrit is. Arthritis Rheum 2006;54:795-801. 
25. Chang A, Hayes K, Dunlop D, et al. Thrust during ambul ation and the progression of knee osteoarthritis. Arthritis 
Rheum 2004;50:3897-903. 
26. Chang A, Hochberg M, Song J, et al. Frequency of var us and valgus thrust and fact ors associated with thrust 
presence in persons with or at higher risk  for knee osteoarthritis. Arthritis Rheum 2010. 
27. Chang A, Hurwitz D, Dunlop D, et al. The relationsh ip between toe-out angle during gait and progression of 
medial tibiofemoral osteoarthr itis. Ann Rheum Dis 2007;66:1271-5. 
28. Intema F, Van Roermund PM, Marijnissen AC, et al. Tissue structure modification in knee osteoarthritis by [CONTACT_450864]: an open 1-year pi[INVESTIGATOR_799]. Ann Rheum Dis 2011;70:1441-6. 
29. van der Woude JA, van Heerwaarden RJ, Spruijt S, et al. Six weeks of continuous joint distraction appears 
sufficient for clinical benefit and cartil aginous tissue repair in the treatment of  knee osteoarthritis. Knee 2016;23:785-91. 
30. van der Woude JA, Welsing PM, van Roermund PM, Custers RJ, Kuchuk NO, La feber FP. Prediction of 
cartilaginous tissue repair after knee joint distraction. Knee 2016;23:792-5. 
31. Chen Y, Sun Y, Pan X, Ho K, Li G. Joint distraction attenuates osteoarthritis by [CONTACT_450865], 
cartilage degeneration and subchondral bone aberra nt change. Osteoarthritis Cartilage 2015;23:1728-35. 
32. van der Woude JA, Wiegant K, van Heerwaarden RJ, et al. Knee joint distraction compared with high tibial 
osteotomy: a randomized controlled trial. Kn ee Surg Sports Traumatol Arthrosc 2016. 
33. Wiegant K, van Roermund PM, Intema F, et al. Sustained clinical and structural benefit after joint distraction in 
the treatment of severe knee osteoarthrit is. Osteoarthritis Cartilage 2013;21:1660-7. 
34. Egger P, Cooper C, Hart DJ, Doyle DV, Coggon D, Specto r TD. Patterns of joint involvement in osteoarthritis of 
the hand: the Chingford Study. J Rheumatol 1995;22:1509-13. 35. Niu J, Zhang Y, LaValley M, Chaisson CE, Aliabadi P,  Felson DT. Symmetry and clustering of symptomatic hand 
osteoarthritis in elderly men and women: the Fr amingham Study. Rheumatology (Oxford) 2003;42:343-8. 
36. McGonagle D, Tan AL, Grainger AJ, Benjamin M. Heberden's nodes and what Heberden could not see: the pi[INVESTIGATOR_450811]. Rheumatology (Oxford) 
2008;47:1278-85. 37. Earnshaw SA, Aladin A, Surendran S, Moran CG. Clos ed reduction of colles fractu res: comparison of manual 
manipulation and finger-trap traction : a prospective, randomized study. J Bone Joint Surg Am 2002;84-A:354-8. 
38. Handoll HH, Madhok R. Closed reduction methods for tr eating distal radial fractures in adults. Cochrane 
Database Syst Rev 2003:CD003763. 39. Cerny M, Marlois R, Theumann N, et al. 3-T direct MR arthrography of the wrist: value of finger trap distraction to assess intrinsic ligament and triangular fibrocar tilage complex tears. Eur J Radiol 2013;82:e582-9. 
40. Leventhal EL, Moore DC, Akelman E, Wolfe SW, Crisco JJ. Conformational changes in the carpus during finger 
trap distraction. J Hand Surg Am 2010;35:237-44. 41. Bashir MA, Arya A. A simple technique for injecting th e small joints of the fingers and thumb using finger traps 
for traction. Ann R Coll Surg Engl 2016;98:343-4. 42. Dreiser RL, Maheu E, Guillou GB. Sensitivity to cha nge of the functional index for hand osteoarthritis. 
Osteoarthritis Cartilage 2000;[ADDRESS_574894] A:S25-8. 
 
Principal Investigator: [CONTACT_70798], Grace, Hsiao-Wei                                                                                             A Pi[INVESTIGATOR_450777] 
 
[ADDRESS_574895] (FDT): construction, validity, reliability, and 
normative data. J Hand Ther 2003;16:12-21. 
44. Kloppenburg M, Maheu E, Kraus VB, et al. OARSI Clinic al Trials Recommendations: Design and conduct of clinical 
trials for hand osteoarthritis. Os teoarthritis Cartilage 2015;23:772-86. 
45. Kellgren JH, Lawrence JS. Radi ological assessment of osteo-arth rosis. Ann Rheum Dis 1957;16:494-502. 
46. Altman RD, Gold GE. Atlas of individual radiographic feat ures in osteoarthritis, revised. Osteoarthritis Cartilage 
2007;[ADDRESS_574896] A:A1-56. 
47. Verbruggen G, Veys EM. Numerical scoring systems for the anatomic evolution of osteoarthritis of the finger 
joints. Arthritis Rheum 1996;39:308-20. 48. Wittoek R, Kroon FPB, Kundakci B,  et al. Report from the Hand Osteoa rthritis Working Group at OMERACT 2018: 
Update on Core Instrument Set De velopment. J Rheumatol 2019;46:1183-7. 
49. Horng YS, Lin MC, Feng CT, Huang CH, Wu HC, Wang JD. Responsiveness of the Michigan Hand Outcomes 
Questionnaire and the Disabilities of the Arm, Shoulder, and Hand questionnaire in patients with hand injury. J Hand 
Surg Am 2010;35:430-6. 50. Kotsis SV, Chung KC. Responsiveness of the Michigan Hand Outcomes Questionnaire and the Disabilities of the Arm, Shoulder and Hand questionnaire in carpal  tunnel surgery. J Hand Surg Am 2005;30:81-6. 
51. Hudak PL, Amadio PC, Bombardier C. Development of an upper extremity outcome measure: the DASH 
(disabilities of the arm, shoulder and hand) [corrected]. Th e Upper Extremity Collaborative  Group (UECG). Am J Ind Med 
1996;29:602-8. 52. Hunter DJ, Lo GH, Gale D, Grainger AJ, Guermazi A, Conaghan PG. The development and reliability of a new 
scoring system for knee osteoarthritis MRI: BLOKS (Bosto n Leeds Osteoarthritis Knee Score). Ann Rheum Dis 2007. 
53. Hunter DJ, Guermazi A, Lo GH, et al. Evolution of semi-quantitative whole joint assessment of knee OA: MOAKS 
(MRI Osteoarthritis Knee Score). Osteoarthritis Cartilage 2011;19:990-1002. 
54. Coxon D, Frisher M, Jinks C, Jordan K, Paskins Z, Peat G. The relative importance of perceived doctor's attitude 
on the decision to consult for symptomatic osteoarthrit is: a choice-based conjoint analysis study. BMJ Open 
2015;5:e009625. 
55. Newgard CD, Haukoos JS. Advanced statis tics: missing data in clinical research --part 2: multiple imputation. Acad 
Emerg Med 2007;14:669-78. 56. Kroon FPB, Boersma A, Boonen A, et al. Performanc e of the Michigan Hand Outcomes Questionnaire in hand 
osteoarthritis. Osteoarthritis Cartilage 2018;26:1627-35. 57. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in 
longitudinal studies: development and va lidation. J Chronic Dis 1987;40:373-83. 
58. Kellgren JH, Lawrence JS. Osteo-arthrosis and disk degeneration in an urban population. Ann Rheum Dis 1958;17:388-97. 59. Dahaghin S, Bierma-Zeinstra SM, Reijman M, Pols HA , Hazes JM, Koes BW. Does hand osteoarthritis predict 
future hip or knee osteoarthrit is? Arthritis Rheum 2005;52:3520-7. 
 